

SUBJECT INDEX FOR VOLUME 44

A

Acetylcholine

activation of ion channels, block by physostigmine, BC3H1 cells, 1051

m3 muscarinic receptor, carboxyl-terminal threonine residues, agonist-induced down-regulation (human), 1158

rapid perfusion, isoflurane, acetylcholine receptor channels, 1056

Acetylcholinesterase, fetal bovine serum, modulation by monoclonal antibody AE-2, carbamate and organophosphate inhibition, 1152

Acquired immunodeficiency syndrome, HIV-1 reverse transcriptase, selective and synergistic inhibition, MKC-442, 895

Adenosine

antagonist 8-cyclopentyl-1,3-dipropylxanthine, elimination of neuromuscular depression, action of exogenous adenosine (frog), 835

inhibition of uptake by ethanol, specificity, one class of nucleoside transporters, 1021

Adenosine triphosphate

-gated ion channel, inhibition by ethanol (frog), 871

-induced increases, intracellular calcium levels in PC-12 cells, chronic ethanol exposure, 405

-induced inhibition of adenylyl cyclase activity, endothelin, C₆ glioma cells, 158

Adenylyl cyclase

activation, molecular cloning, serotonin receptor (mammal), 229

cloned human 5-HT_{1Dα} and 5-HT_{1Dβ} receptors, dual coupling, fibroblasts (mouse), 575

Adenylyl cyclase

cAMP and, calcium entry via L-type calcium channels, cardiac myocytes (chicken), 689

coupling of splice variant, somatostatin receptor 2 subtype, 1016

endothelin- and ATP-induced inhibition, C₆ glioma cells, 158

G protein amino-terminal α_{12}/α_{13} , amino acids, regulation of α , activity, 255

molecular cloning and functional expression, μ -opioid receptor, brain (rat), 8

Adrenal gland

α_1 -adrenergic receptor subtype distribution (human), 70

sequential activation of *c-fos*, proenkephalin and tyrosine hydroxylase, metrazole (rat), 328

turkey, angiotensin receptors, pharmacological distinction from mammalian receptors, 1

Adrenoceptors

alpha-1

comparison of subtypes and signal transduction, neuronal cell lines, 76

density and receptor-mediated calcium response, astroglial cells (rat), 247

heterogeneous expression, nephron segments (rat), 926

alpha-1A, liver membranes (guinea pig), 589

alpha-1B gene induction, cycloheximide, transcription of DDT₁ MF-2 smooth muscle cells, 1105

alpha-1 and *alpha*-2, selective irreversible binding, chloroethylclonidine, 1165

alpha-1B and *alpha*-1D, coupling to multiple signaling pathways, G protein and cell type specific, 784

alpha-2

coupling to cyclic AMP-dependent reporter gene, JEG-3 cells, 802

subtype distribution, multiple tissues (human), 70

beta, endocytosis and exocytosis of transferrin, antimycin A (human), 364

beta-1 and *beta*-2, regulation by dexamethasone, C₆ glioma cells, 1085

beta-2

amino acid substitutions at position 312, seventh hydrophobic segment, 111

mutants, desensitization with long-term epinephrine treatment, 569

beta-3

gene characterization (human), 264

structural and conformational features, signal transduction, 1094

Adrenocorticotrophic hormone, sequential activation of *c-fos*, metrazole, adrenal gland (rat), 328

Adriamycin, cytochrome P450 2B1-mediated one-electron reduction, liver microsomes (rat), 1267

ω -Agatoxin IVB, structure and properties, antagonist, P-type calcium channels (rat), 681

Agelenopsis aperta, structure and properties of ω -agatoxin IVB, antagonist, P-type calcium channels (rat), 681

Agonists

discrimination from antagonist binding sites, point mutation in 7th hydrophobic domain, point mutation in 7th hydrophobic domain, 934

dual effects as antagonists, novel neurotensin mimetics, pharmacological studies, 1036

-induced state of δ -opioid receptor, discrimination, opioid peptides and opiate alkaloids, 166

Albumin, negatively charged, anti-HIV-1 activity (human), 1003

Alkaloids, opioid, agonist-induced state, δ -opioid receptor, 166

Alkanols, cycloalkanemethanols, volume- and length-dependent loss of activity, *Torpedo* nicotinic acetylcholine receptor, 1219

Amiloride

analogues, inhibition of Na-K-Cl cotransport, stimulation of cyclic AMP-dependent protein kinase, 393

analogues and anti-ischemic properties of inhibitor, pharmacological characterization, Na⁺/H⁺ antiporter isoforms, 1041

Amines, secretory vesicle biogenic, interaction with plasma membrane, amphetamine derivatives, 1227

Amino acids

naturally occurring substitution, functional effects, thymidylate synthase (human), 316

regulation of α , activity, G protein amino-terminal α_{12}/α_{13} chimeras, 255

substitutions at position 312, seventh hydrophobic segment, β_1 -adrenergic receptor, 111

transport systems, nitric oxide synthase inhibitors, endothelial cells, 615

 γ -Aminobutyric acid

-induced chloride currents

benzodiazepine site agonists, 866

decay and U-93631, recombinant GABA_A receptors (rat), 860

regional sensitivity, *t*-butylbicyclophosphoro[³⁵S]thionate binding, GABA_A receptor subunit (human, rat), 87

α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, kainate and glutamate receptors, cyclothiazide and concanavalin A, 504

5-Amino-4-imidazolecarboxamide riboside, potentiation of metabolism and anti-HIV activity, 2',3'-dideoxyinosine (human), 30

4-Amino-8-(β -D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine, inhibition of 5-phosphoribosyl-1-pyrophosphate synthetase (human, mouse), 479

- Ammonium, quaternary, blockers, batrachotoxin-modified Na⁺ channels, 667
- Amphetamine, derivatives, interaction plasma membrane and secretory vesicle biogenic amine transporters, 1227
- Amthamine, activation model for histamine H₂ receptor, histamine H₂ receptor agonists, 886
- Amylin, high affinity binding sites in brain (rat), 493
- Analgesia, cannabinoid receptor-binding, structure-activity relationships, 1008
- Anandamide, inhibition of calcium currents, partial agonist, N18 cells, 498
- Anesthetics
 isoflurane, positive modulation, human GABA_A and glycine receptors, 628
 steroids, role of cytochrome P450 in regulation, brain (rat), 1077
- Angiotensin, receptor isoform from turkey adrenal gland, pharmacological distinction, mammalian receptors, 1
- Anticancer agents, DNA-binding, antihelicase action, guanosine-cytidine intercalator binding, 1064
- Antiestrogens, inhibition of replication, retroviral Moloney murine leukemia virus, 324
- Antifolate, resistance, mutation in Chinese hamster ovary cells, ethylmethanesulfonate exposure, 13
- Antimycin A, endocytosis and exocytosis of transferrin, internalization and externalization, β -adrenergic receptors, 364
- Anxiety, premenstrual, GABA_A receptor regulation, pregnanolone (chick), 191
- Aorta, α_2 -adrenergic receptor subtype distribution (human), 70
- Arachidonic acid, glutamate and, formation of noradrenalin-induced inositol phosphates, striatal astrocytes, 1176
- Arrhythmia, delayed rectifier K⁺ channel, terfenadine and its metabolites, heart (human), 1240
- Artery, human and bovine, expression of mRNA, 5-HT_{1D} receptor subtype, 242
- Aryl hydrocarbon, receptor nuclear translocator protein, dioxin receptor action, 511
- Aspartate, mutation at residue 89, somatostatin receptor subtype 2, Na⁺ regulation (mouse), 380
- Astrocytes, striatal, formation of noradrenalin-induced inositol phosphates, arachidonic acid and glutamate, 1176
- Astroglial cells, receptor-mediated calcium response, quantitative relationship, α_1 -adrenergic receptor density, 247
- Azidopamil, σ_1 binding site, 966
- B**
- B29,B29'-suberoyl-insulin, heterogeneity of insulin receptors, tissues (rat), 271
- Baculovirus, -Sf-21 insect cell system, pharmacological characterization, cloned human NK-2 neurokinin A receptor, 356
- Barbiturate, role of β subunit, pharmacology, GABA_A receptors (human), 1211
- Barium, blockade of clonal potassium channel, regulation, critical pore residue, 180
- Batrachotoxin-modified Na⁺ channels, quaternary ammonium blockers, 667
- BC3H1 cells, physostigmine block of ion channels, acetylcholine, 1051
- Benzodiazepine
 GABA_A receptors
 regulation, pregnanolone (chick), 191
 role of γ subunits (human), 437
 -insensitive GABA chloride channels, inhibition of flux by zinc, cortical and cerebellar microsacs (rat), 876
 role of β subunit, pharmacology, GABA_A receptors (human), 1211
 site agonists, GABA-induced chloride currents, 866
- Benzoquinoid, tyrosine kinase inhibitors, blockers of cardiac muscarinic receptor function (bullfrog), 595
- Bleomycin, resistance protein in mammalian cells, nuclear localization, *Streptocolloteichus hindustanus*, 1135
- Bradykinin
 cloned receptor, mixed B₁ and B₂ pharmacological selectivity (mouse), 346
 indirect inhibition of cAMP generation, glomeruli and mesangial cells (rat), 818
 -induced increases, intracellular calcium levels in PC-12 cells, chronic ethanol exposure, 405
- Brain
 antipeptide antibodies, μ -opioid receptors (cattle), 796
 cerebral cortex and cerebellum, agonist response kinetics, NMDA receptors (rat), 1252
 cortical and cerebellar microsacs, inhibition of flux by zinc, benzodiazepine-insensitive GABA chloride channels (rat), 876
 cytochrome P450, regulation, anesthetic steroid levels (rat), 1077
 D1 dopamine receptor expression, identical D1A and D1B receptor mRNAs (opossum), 918
 distribution and modulation, cytochrome P-450 and epoxide hydrolase mRNAs, 990
 high affinity amylin binding sites (rat), 493
 membrane, G protein activation, A₁ adenosine receptor agonists (cattle), 115
 membranes and neuroblastoma cells, BW373U86, G protein-mediated actions, 827
 molecular cloning and functional expression, μ -opioid receptor (rat), 8
 nonselective-type endothelin, alternative transcript (rat), 533
 opioid receptors, *in situ* interactions, guanine nucleotide-binding protein G_o (rat), 62
 opioid receptor types and subtypes, differential down- and up-regulation, buprenorphine (rat), 173
 regulation of nitric oxide synthase, nitric oxide (cattle), 124
 striatal astrocytes, formation of noradrenalin-induced inositol phosphates, arachidonic acid and glutamate, 1176
 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, 5-HT_{1C} receptor density and mRNA levels, choroid plexus epithelial cells (rat), 725
 α -Bungarotoxin-sensitive acetylcholine receptors, retina (chick), 1046
 Buprenorphine, differential down- and up-regulation, opioid receptor types and subtypes (rat), 173
 t-Butylbicyclophosphoro[³⁵S]thionate, binding and GABA_A receptor α subunit, regional γ -aminobutyric acid sensitivity (human, rat), 87
 BW373U86, G protein-mediated actions, brain membranes, neuroblastoma cells, 827
- C**
- Cadmium, cisplatin resistance and, mouse metallothionein, cell survival in CHO cells, 44
- Calcium
 cAMP levels and, P_{2U} purinergic receptors, protein kinase C and glioma cells (rat), 1185
 -dependent and -independent protein kinase isozymes, ligand and substrate specificity (insect), 298
 dual coupling in fibroblasts, cloned human 5-HT_{1D} and 5-HT_{1D} receptors (mouse), 575
 enkephalin gene transcription, DNase I-hypersensitive sites, chromaffin cells (cattle), 545
 entry via L-type calcium channels, adenylyl cyclase and cAMP, cardiac myocytes (chicken), 689
 intracellular, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, ventricular contractile responses (chick), 1142
 intracellular levels in PC-12 cells, ATP- and bradykinin-induced increases, chronic ethanol exposure, 405
 mobilization induced by inositol-1,3,4,5-tetrakisphosphate, receptor, SH-SY5Y neuroblastoma cells, 810
 receptor-mediated response, α_1 -adrenergic receptor density, quantitative relationship (rat), 247

- red cell transport, irreversible modification, phenylglyoxal, 399
 release channel, activating and deactivating effects, natural ryanodine congeners (rabbit), 412
 responses mediated by signal transduction, endothelin receptors, follicular membranes of *Xenopus* oocytes, 153
 role of G_i and, endothelin- and ATP-induced inhibition, adenylyl cyclase activity in C_6 cells, 158
- Calcium channels**
 modulation of NMDA receptor channel function, nitrendipine, neurons (mouse), 443
 P-type, ω -agatoxin IVB, structure and properties (rat), 681
 voltage-sensitive, pharmacological characterization, ω -grammotoxin SIA, 451
- Calcium currents**
 inhibition by anandamide, partial agonist, N18 cells, 498
 inhibition by 3-isobutyl-1-methylxanthine, cAMP, neuronal and endocrine cells, 622
- Cannabinoid**
 anandamide, inhibition of calcium currents, partial agonist in N18 cells, 498
 receptor-binding and analgesic activity, structure-activity relationships, 1008
- Carbamate**, modulation by monoclonal antibody AE-2, fetal bovine serum acetylcholinesterase, 1152
- Carbonic anhydrase IV**, chemical properties, 901
- Catecholamines**
 ligand binding and functional studies, σ -like receptor, phenylaminotetralins, 1232
 regulation of β adrenoreceptors, dexamethasone, C_6 glioma cells, 1085
- 293 cells, transfected, paradoxical regulation, dopamine receptors, 371
- Central nervous system**, *Xenopus*, reconstitution of glutamate receptor proteins, artificial bilayers, 142
- Cerebellum**
 granule cells
 agonist-induced down-regulation, m_2 - and m_3 -muscarinic acetylcholine receptor, 940
 developmental changes, metabotropic glutamate receptors, 981
 regulation of nitric oxide synthase, nitric oxide (cattle), 124
- Chimera**, G protein amino-terminal α_{12}/α_{11} , amino acids, regulation of α_1 activity, 255
- Chinese hamster ovary cells**
 cell survival, cisplatin and cadmium resistance, mouse metallothionein, 44
 mutations leading to antifolate resistance, ethylmethanesulfonate exposure, 13
- Chloride channels**, benzodiazepine-insensitive, inhibition of flux by zinc, cortical and cerebellar microsacs (rat), 876
- Chloride currents**
 GABA-induced
 benzodiazepine site agonists, 866
 decay and U-93631, recombinant GABA_A receptors (rat), 860
- Chlorocresol**, activator, ryanodine receptor-mediated Ca^{2+} release, 1192
- Chloroethylclonidine**, selective irreversible binding, α -1 and -2 adrenoreceptor subtypes, 1165
- (2-Chloroethyl)-3-sarcosinamide-1-nitrosourea, transport in human glioma cell line SK-MG-1, mediation, epinephrine-sensitive carrier system, 204
- Choroid plexus**, epithelial cells, 5-HT_{1C} receptor density, mRNA levels (rat), 725
- Chromaffin cells**, enkephalin gene transcription, DNase I-hypersensitive sites (cattle), 545
- Cisplatin**, cadmium resistance and, mouse metallothionein, cell survival in CHO cells, 44
- Clara cells**, differentiation, postnatal changes in expression and distribution, pulmonary cytochrome P450 monooxygenases (rabbit), 51
- α -Cobratoxin, phospholipase A₂ activity, thymopoietin preparations, 678
- Colon**, α_2 -adrenergic receptor subtype distribution (human), 70
- Colonic neoplasms**, cytotoxicity of 5-fluorouracil/interferon- α -2a, *N*-(phosphonacetyl)-L-aspartate (human), 1070
- Concanavalin A**, cyclothiazide and, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate-preferring glutamate receptors, 504
- Copper-treated vitamin E- and selenium-deficient rats**, electron spin resonance, free radical generation, 222
- COS-7 cells**, estrogenic activity, commonly occurring plant flavonoids, 37
- Curare**, interaction with nicotinic acetylcholine receptor, selective enhancement (mouse), 237
- Cyclic AMP**
 adenylyl cyclase and, calcium entry via L-type calcium channels, cardiac myocytes (chicken), 689
 cytosolic Ca^{2+} and, P_{2U} purinergic receptors, protein kinase C and glioma cells (rat), 1185
 -dependent protein kinase
 enhancement, GABA type A receptor currents, 1202
 inhibition of Na-K-Cl cotransport, amiloride analogues, 393
 -dependent reporter gene, coupling of α_2 -adrenergic receptor subtypes, JEG-3 cells, 802
 elevation in PC12 cells, multiple mechanisms, desensitization of A2a adenosine receptor, 950
 functional role of M_2 muscarinic receptor, smooth muscle, ileum (guinea pig), 102
 indirect inhibition of generation by bradykinin, glomeruli and mesangial cells (rat), 818
 inhibition of adenosine uptake by ethanol, specificity, one class of nucleoside transporters, 1021
 inhibition of sustained calcium current, 3-isobutyl-1-methylxanthine, neuronal and endocrine cells, 622
 molecular cloning and functional expression, μ -opioid receptor, brain (rat), 8
- Cyclic GMP-elevating agents**, inhibition of cyclic nucleotide phosphodiesterase isoforms, thymocyte proliferative response, 1027
- Cycloalkanemethanols**, volume- and length-dependent loss of activity, alkanols, *Torpedo* nicotinic acetylcholine receptor, 1219
- Cycloheximide**, induction of α -1B adrenoreceptor gene, transcription, DDT₁ MF-2 smooth muscle cells, 1105
- 8-Cyclopentyl-1,3-dipropylxanthine, elimination of neuromuscular depression, action of exogenous adenosine (frog), 835
- Cyclosporin A**, immunosuppressive activity, lysophospholipid-mediated inhibition, Na^+ , K^+ -ATPase, 605
- Cyclothiazide**, concanavalin A and, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate-preferring glutamate receptors, 504
- CYP1A1**, negative regulatory element, interaction with protein, liver and hepatoma cells, 560
- Cytidine-guanosine intercalator binding**, antihelicase action, DNA-binding anticancer agents, 1064
- Cytochrome P-450**
 block of gene transcription, RU486 (rat), 775
 cytokine down-regulation of major enzymes, adult hepatocytes in primary culture (human), 707
 liver microsomal, reductive metabolism, zonisamide (human), 216
 regional distribution and expression modulation, epoxide hydrolase mRNA, brain (rat), 990
 regulation, level of anesthetic steroids, brain (rat), 1077
- Cytochrome P-450 2B1-mediated one-electron reduction**, Adriamycin, liver microsomes (rat), 1267
- Cytochrome P-450 2C7**, induction of mRNA, growth hormone and vitamin A, primary hepatocytes (rat), 997
- Cytochrome P-450 monooxygenases**, pulmonary, postnatal changes in expression and distribution, Clara cell differentiation (rabbit), 51

Cytokines, down-regulation of major cytochrome P-450 enzymes, adult hepatocytes in primary culture (human), 707
 Cytosol, Ca^{2+} and cAMP levels, P_{2U} purinergic receptors, protein kinase C and glioma cells (rat), 1185

D

DAGO, molecular cloning and functional expression, μ -opioid receptor, brain (rat), 8
 4-DAMP mustard, functional role of M_2 muscarinic receptor, smooth muscle, ileum (guinea pig), 102
 α -Dendrotoxin, binding site interaction with tityustoxin-K α , cloned Kv1.2 K $^+$ channel, 430
 2'-Deoxyguanosine, phosphorylation of enantiomers of carbocyclic analog, HSV-1 and uninfected cells, 1258
 Dexamethasone, regulation of β_2 adrenoceptors, C $_6$ glioma cells, 1085
 2',3'-Dideoxycytidine, anti-HIV-1 therapy, peripheral neuropathy, PC12 cells, 702
 2',3'-Dideoxyinosine, potentiation of anti-HIV activity, 5-amino-4-imidazolecarboxamide riboside (human), 30
 Dihydrofolate reductase
 alteration of pre-mRNA splicing, 5-fluorouracil, quantitative PCR (human), 22
 mutations leading to antifolate resistance, ethylmethanesulfonate exposure, CHO cells, 13
 Dihydropyridine, nitrendipine, modulation of NMDA receptor channel function, neurons (mouse), 443
 1,25-Dihydroxyvitamin D $_3$, transcription and expression, inositol triphosphate gene, HL-60 cells, 292
 Dioxin, aryl hydrocarbon receptor nuclear translocator protein, 511
 Disulfiram, peptide α -amidation, peptidylglycine α -hydroxylating monooxygenase, 972
 DNA-binding anticancer agents, antihelicase action, guanosine-cytidine intercalator binding, 1064
 DNA, complementary
 β_2 -adrenergic receptor gene characterization (human), 264
 human Ah receptor, cloning and expression, 911
 DNase I-hypersensitive sites, enkephalin gene transcription, chromaffin cells (cattle), 545
 DNA topoisomerases, I and II inhibition by intropicine, early clinical trials, 767
 Dopamine
 identical receptor mRNAs, cloning and characterization, kidney and brain (opossum), 918
 modulation of novel subtype, sulfonylurea-sensitive potassium channels (rat), 907
Drosophila, nervous system, muscarinic acetylcholine receptor, immunocytochemistry, 716
 DT-diaphorase
 pH-dependent inactivation, mitomycin C and porfirimycin, 1128
 role of NAD(P)H:(quinone acceptor) oxidoreductase, activation of mitomycin C, acidic conditions, 210

E

Electron spin resonance, free radical generation, copper-treated vitamin E- and selenium-deficient rats, 222
 Emopamil, σ_1 binding site, 966
 Endocrine cells, inhibition of sustained calcium current, 3-isobutyl-1-methylxanthine, 622
 Endoplasmic reticulum, postnatal changes in expression and distribution, pulmonary cytochrome P450 monooxygenases, Clara cell differentiation (rabbit), 51
 Endothelial cells, amino acid transport, actions of nitric oxide synthase inhibitors (pig), 615
 Endothelin
 ATP-induced inhibition of adenylyl cyclase activity, role of G_i and calcium, C $_6$ glioma cells, 158
 modulation of receptor number, phosphoramidon, Swiss 3T3 fibroblasts, 422

nonselective-type receptor, alternative transcript, brain (rat), 533
 receptors in follicular membranes, calcium responses, *Xenopus* oocytes, 153
 receptor subtypes, expression, saphenous vein (rabbit), 959
 type A receptors, MMQ cells, 285
 Enkephalin, gene transcription, DNase I-hypersensitive sites, chromaffin cells (cattle), 545
 Enzymes, membrane-bound, chemical properties, carbonic anhydrase IV, 901
 Epinephrine
 long-term treatment and desensitization, β_2 -adrenoceptor mutants, 569
 -sensitive carrier system, transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea, human glioma cell line SK-MG-1, 204
 Epithelial cells, choroid plexus, 5-HT $_{1C}$ receptor, density and mRNA levels (rat), 725
 Epitopes, allosteric interactions, use of chimeric muscarinic receptors, 583
 Epoxide hydrolase, mRNA in brain, distribution and modulation, cytochrome P-450 (rat), 990
 Estrogen, estrogenic activity, commonly occurring plant flavonoids, HeLa and COS-7 cells, 37
 Ethanol
 chronic exposure, ATP- and bradykinin-induced increases, intracellular calcium levels in PC-12 cells, 405
 inhibition, neuronal ATP-gated ion channel (frog), 871
 inhibition of adenosine uptake, specificity, one class of nucleoside transporters, 1021
 δ -opioid receptor gene expression, neuronal cell lines, 1119
 Ethylmethanesulfonate, exposure of Chinese hamster ovary cells, mutations leading to antifolate resistance, 13

F

Fat, α_2 -adrenergic receptor subtype distribution (human), 70
 Fibroblasts
 dual coupling, cloned human 5-HT $_{1D\alpha}$ and 5-HT $_{1D\beta}$ receptors (mouse), 575
 Swiss 3T3, modulation of number of endothelin receptors, phosphoramidon, 422
 FK888, pulmonary neurokinin type 1 receptors, characterization (guinea pig), 539
 Flavonoids, plant, estrogenic activity, HeLa and COS-7 cells, 37
 2'- β -Fluoro-2',3'-dideoxynucleosides, anti-HIV activity, enhanced stimulation by ribavirin, 5'-phosphorylation, 519
 5-Fluorouracil
 alteration of dihydrofolate reductase pre-mRNA splicing, quantitative PCR (human), 22
 -interferon- α -2a, cytotoxicity in colon cancer cell lines, N-(phosphonacetyl)-L-aspartate (human), 1070
 Free radicals, generation, electron spin resonance, copper-treated vitamin E- and selenium-deficient rats, 222
 β -Funaltrexamine-labeled μ -opioid receptors, species variations, complex-type N-linked oligosaccharides (guinea pig, rat, mouse), 749

G

Galactose, drug targeting, lipoprotein-like lipid particles (human), 486
 Gallamine, epitopes in allosteric interactions, use of chimeric muscarinic receptors, 583
 Gap junction, calcium responses mediated by signal transduction, endothelin receptors, follicular membranes of *Xenopus* oocytes, 153
 Gene
 β_2 -adrenergic receptor (human), 264
 cAMP-dependent reporter, coupling of α_2 -adrenergic receptor subtypes, JEG-3 cells, 802
 c-fos, induction of sequential activation, metrazole (rat), 328
 cytochrome P-450, block of transcription, RU486 (rat), 775
 enkephalin, transcription in chromaffin cells, DNase I-hypersensitive sites (cattle), 545

- inositol trisphosphate, expression and transcription, 1,25-dihydroxy-vitamin D₃, 292
- mouse metallothionein, cisplatin and cadmium resistance, cell survival in CHO cells, 44
- Glioma**
- C₆ cells, regulation of β adrenoreceptors, dexamethasone, 1085
- endothelin- and ATP-induced inhibition, adenylyl cyclase activity, 158
- P_{2U} purinergic receptors on glioma cells, cytosolic Ca²⁺ and cAMP levels, protein kinase C (rat), 1185
- transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea, mediation, epinephrine-sensitive carrier system, 204
- Glomeruli, indirect inhibition of cAMP generation, bradykinin (rat), 818
- Glucocorticoid, sequential activation of *c-fos*, metrazole, adrenal gland (rat), 328
- Glutamate**
- arachidonic acid and, formation of noradrenalin-induced inositol phosphates, striatal astrocytes, 1176
- receptor protein reconstitution, artificial bilayers, *Xenopus* central nervous system, 142
- receptor subunit mRNA expression, diversity, hippocampal CA1 neurons (rat), 308
- Glycine, inhibitory receptor, extracellular disulfide loop motif, 198
- G proteins**
- activation by A₁ adenosine receptor agonists, brain membranes (cat-tle), 115
- amino-terminal α_2/α_c chimeras, amino acids, regulation of α_c activity, 255
- aspartate mutation at residue 89, somatostatin receptor subtype 2, Na⁺ regulation of agonist binding (mouse), 380
- cloned somatostatin receptors SSTR4 and SSTR5 (human), 385
- coupled functions, modification by low-pH pretreatment of mem-branes, NG108-15 cells, 731
- coupling of α_{1B} - and α_{1D} -adrenergic receptors, multiple signaling pathways, 784
- dual coupling in fibroblasts, cloned human 5-HT_{1D α} and 5-HT_{1D β} receptors (mouse), 575
- in situ* interactions with G_o, brain opioid receptors (rat), 62
- mediated actions, BW373U86, brain membranes and neuroblastoma cells, 827
- role of G_i and calcium, endothelin- and ATP-induced inhibition, adenylyl cyclase activity in C₆ cells, 158
- ω -Grammotoxin, SIA, pharmacological characterization, voltage-sen-sitive calcium channel responses, 451
- Granule cells**
- cerebellar
- agonist-induced down-regulation, m₂- and m₃-muscarinic acetyl-choline receptor, 940
- developmental changes, metabotropic glutamate receptors, 981
- Growth hormone, vitamin A and, induction of P4502C7 mRNA, pri-mary hepatocytes (rat), 997
- Guanosine-cytidine intercalator binding, antihelicase action, DNA-binding anticancer agents, 1064
- Guanosine-5'-O-(3-[³²S]thio)triphosphate, binding, G protein activa-tion in brain membranes, A₁ adenosine receptor agonists (cattle), 115
- Guanylate cyclase, regulation of nitric oxide synthase, nitric oxide (cattle), 124
- H**
- Heart**
- α_2 -adrenergic receptor subtype distribution (human), 70
- angiotensin II receptor expression, *Xenopus laevis*, 277
- block of rapidly activating delayed rectifier K⁺ channel, verapamil, 642
- delayed rectifier K⁺ channel, terfenadine and its metabolites (hu-man), 1240
- muscarinic receptor function, blockers, benzoquinoid tyrosine kinase inhibitors (bullfrog), 595
- myocytes, calcium entry via L-type calcium channels, adenylyl cy-clase and cAMP (chicken), 689
- HeLa cells, estrogenic activity, commonly occurring plant flavonoids, 37
- Helicase, antihelicase action, DNA-binding anticancer agents, guano-sine-cytidine intercalator binding, 1064
- Hepatocytes**
- induction of P4502C7 mRNA, growth hormone, vitamin A (rat), 997
- primary culture, cytokine down-regulation, major cytochrome P-450 enzymes (human), 707
- Hepatoma, CYP1A1 negative regulatory element, interaction with pro-tein, 560
- Herpes simplex virus, type 1, phosphorylation of enantiomers, carbo-cyclic analog of 2'-deoxyguanosine, 1258
- Hippocampus, live CA1 neurons, diversity of expression, glutamate receptor subunit mRNA expression (rat), 308
- Histamine, H₂ receptor agonists, activation model, histamine H₂ recep-tor, 886
- Histidine, naturally occurring amino acid substitution, functional ef-fects, thymidylate synthase (human), 316
- HIV-1**
- anti-HIV-1 therapy, peripheral neuropathy, PC12 cells, 702
- drug-resistance patterns, 1-[(2-hydroxyethoxy)methyl]-6-(phenyl-thio)thymine derivatives, 694
- reverse transcriptase, selective and synergistic inhibition, MKC-442, 895
- HL-60 cells, inositol trisphosphate gene, expression and transcription, 292
- Human immunodeficiency virus**
- anti-virus activity of purine 2'- β -fluoro-2',3'-dideoxynucleosides, en-hanced simulation by ribavirin, 5'-phosphorylation, 519
- potentiation of anti-HIV activity, 5-amino-4-imidazolecarboxamide riboside, 2',3'-dideoxyinosine (human), 30
- Human immunodeficiency virus-1, anti-HIV-1 activity, negatively charge serum albumins (human), 1003
- Hydrocarbons, polycyclic aromatic, interactions with indolo[3,2-*b*]car-bazoles, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin binding, liver (rat), 336
- 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine, derivatives, HIV-1 drug-resistance patterns, 694
- I**
- Ifenprodil, discrimination of subtypes, NMDA receptor, heteromeric receptors (rat), 851
- Ileum**
- α_2 -adrenergic receptor subtype distribution (human), 70
- functional role, M₂ muscarinic receptor (guinea pig), 102
- Immunocytochemistry, *Drosophila* nervous system, muscarinic acetyl-choline receptor, 716
- Immunosuppression, cyclosporin A, lysophospholipid-mediated inhi-bition, Na⁺/K⁺-ATPase, 605
- Indole analogs, molecular mechanism of δ -selectivity, nonpeptide opioids, 1246
- Indolo[3,2-*b*]carbazoles, interactions with related polycyclic aromatic hydrocarbons, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin binding, liver (rat), 336
- Inositol-1,3,4,5-tetrakisphosphate, induction of calcium mobilization via receptor, SH-SY5Y neuroblastoma cells, 810
- Inositol phosphates, noradrenalin-induced, role of arachidonic acid and glutamate, striatal astrocytes, 1176
- Inositol trisphosphate, gene expression and transcription, 1,25-dihy-droxyvitamin D₃, HL-60 cells, 292

- Insulin, heterogeneity of receptors, tissues, B29,B29'-suberoyl-insulin (rat), 271
- Interferon- α -2a/5-fluorouracil, cytotoxicity in colon cancer cell lines, N-(phosphonacetyl)-L-aspartate (human), 1070
- Intropicine, dual topoisomerase I and II inhibition, early clinical trials, 767
- Ion channel
ATP-gated, inhibition by ethanol (frog), 871
inhibitory glycine receptor, extracellular disulfide loop motif, 198
physostigmine block, activation by acetylcholine, BC3H1 cells, 1051
- Ischemia, inhibitor exhibiting anti-ischemic properties, pharmacological characterization, Na⁺/H⁺ antiporter isoforms, 1041
- 3-Isobutyl-1-methylxanthine, inhibition of sustained calcium current, cAMP, neuronal and endocrine cells, 622
- Isoflurane
acetylcholine receptor channels, rapid perfusion of acetylcholine, 1056
positive modulation, human GABA_A and glycine receptors, 628
- Isoproterenol, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, cardiac myocyte intracellular calcium, ventricular contractile responses (chick), 1142
- ### J
- JEG-3 cells, coupling of α_2 -adrenergic receptor subtypes, cAMP-dependent reporter gene, 802
- Jejunum, α_2 -adrenergic receptor subtype distribution (human), 70
- ### K
- Kainate, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and glutamate receptors, cyclothiazide and concanavalin A, 504
- Kidney
 α_1 -adrenergic receptor subtype distribution (human), 70
D1 dopamine receptor expression, identical D1A and D1B receptor mRNAs (opossum), 918
- ### L
- Leukemia virus, Moloney murine, inhibition of replication, antiestrogens, 324
- Ligands
binding sites
neuronal nicotinic acetylcholine receptors, chimeric α subunits, 657
role of threonine 342 in helix 7, 5-HT_{1D} receptor, 882
binding specificity, amino acid substitutions at position 312, β_2 adrenergic receptor, 111
inhibitory glycine receptor, extracellular disulfide loop motif, 198
substrate specificity and, calcium, protein kinase isozymes (insect), 298
- Lipid, lipoprotein-like particles, drug targeting (human), 486
- Lipoprotein-like lipid particles, drug targeting (human), 486
- Liver
 α_2 -adrenergic receptor subtype distribution (human), 70
CYP1A1 negative regulatory element, interaction with protein, 560
drug targeting, lipoprotein-like lipid particles (human), 486
2,3,7,8-tetrachlorodibenzo-*p*-dioxin binding, interactions, indolo[3,2-*b*]carbazoles and related polycyclic aromatic hydrocarbons (rat), 336
- Liver, membranes, α -1A adrenoceptors (guinea pig), 589
- Liver microsomes
cytochrome P450, reductive metabolism, zonisamide (human), 216
cytochrome P450 2B1-mediated one-electron reduction, Adriamycin (rat), 1267
- Lung
 α_2 -adrenergic receptor subtype distribution (human), 70
cytochrome P450 monooxygenases, postnatal changes in expression and distribution, Clara cell differentiation (rabbit), 51
neurokinin type 1 receptors, [³H]FK888, characterization (guinea pig), 539
- Lysophospholipid-mediated inhibition, Na⁺,K⁺-ATPase, immunosuppressive activity, cyclosporin A, 605
- ### M
- Macrophages, poly(A⁺) RNA, pore-forming P₂₂ purinoceptor, *Xenopus* oocytes, 93
- Mammalian cells, bleomycin resistance protein, nuclear localization, *Streptococcus hindustanus*, 1135
- Mesangial cells, indirect inhibition of cAMP generation, bradykinin (rat), 818
- Metallothionein, mouse, cisplatin and cadmium resistance, cell survival in CHO cells, 44
- Methotrexate, mutations leading to antifolate resistance, ethylmethanesulfonate exposure, CHO cells, 13
- Methylurapidil, α -1A adrenoceptors, liver membranes (guinea pig), 589
- Metrazole, induction of sequential activation, c-fos/proenkephalin/tyrosine hydroxylase gene expression, adrenal gland (rat), 328
- Mianserin, 5-HT_{1C} receptor density and mRNA levels, choroid plexus epithelial cells (rat), 725
- Microtubules, inhibition of assembly, spongistatin 1, binding of vinblastine to tubulin (sponge), 757
- Migraine, expression of mRNA, 5-HT_{1D} receptor, human and bovine arteries, 242
- Mitomycin C
pH-dependent inactivation, DT-diaphorase, 1128
role of NAD(P)H:(quinone acceptor) oxidoreductase, activation under acidic conditions, 210
- Mitosis, inhibition by spongistatin 1, binding of vinblastine to tubulin (sponge), 757
- MKC-442, selective and synergistic inhibition, HIV-1 reverse transcriptase, 895
- MMQ cells, type A endothelin receptors, 285
- Monoclonal antibodies, AE-2, modulation of carbamate and organophosphate inhibition, fetal bovine serum acetylcholinesterase, 1152
- Multidrug resistance, reversal of *Vinca* alkaloid resistance, *N*-substituted phenoxazines, 552
- Muscle
DDT, MF-2 cells, α -1B gene induction, cycloheximide, 1105
elimination of neuromuscular depression, action of exogenous adenosine, 8-cyclopentyl-1,3-dipropylxanthine (frog), 835
skeletal, α_2 -adrenergic receptor subtype distribution (human), 70
- Muscle, skeletal, high affinity amylin binding sites, brain (rat), 493
- Muscle, smooth, ileum, functional role, M₂ muscarinic receptor (guinea pig), 102
- Mutagenesis, selective enhancement, interaction of curare, nicotinic acetylcholine receptor (mouse), 237
- Myocytes
cardiac, calcium entry via L-type calcium channels, adenylyl cyclase and cAMP (chicken), 689
intracellular calcium, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, isoproterenol (chick), 1142
- ### N
- Na⁺,K⁺-ATPase, lysophospholipid-mediated inhibition, immunosuppressive activity, cyclosporin A, 605
- NAD(P)H:(quinone acceptor) oxidoreductase, role in activation of mitomycin C, acidic conditions, 210
- Na⁺/H⁺ antiporter, pharmacological characterization, amiloride analogs, inhibitor with anti-ischemic properties, 1041
- Na⁺/K⁺-ATPase, interaction of tricyclic drug analogs, synaptic plasma membranes (rat), 129
- NB41A3 cells, comparison of α_1 -adrenergic receptor subtypes, signal transduction, 76
- Nephron, segments, heterogeneous expression, α_1 -adrenoceptor subtypes (rat), 926
- Nervous system, *Drosophila*, muscarinic acetylcholine receptor, immunocytochemistry, 716

- Neuroblastoma**
 brain membranes and, BW373U86, G protein-mediated actions, 827
 partial agonist, anandamide, inhibition of calcium currents, 498
 SK-N-SH cells, interactive down-regulation, μ - and δ -opioid receptors, 461
- Neurokinin A, NK-2 receptor, pharmacological characterization, baculovirus/Sf-21 insect cell system, 356**
- Neuromedin B, receptor antagonists, substituted somatostatin analogues (rat), 841**
- Neuronal cells**
 comparison of α_1 -adrenergic receptor subtypes, signal transduction, 76
 inhibition of sustained calcium current, 3-isobutyl-1-methylxanthine, 622
- Neurons**
 agonist response kinetics, NMDA receptors (rat), 1252
 cell line, δ -opioid receptor gene expression, ethanol, 1119
 hippocampal CA1, diversity, glutamate receptor mRNA expression (rat), 308
 modulation of NMDA receptor channel function, nitrendipine (mouse), 443
 pharmacological characterization, ω -grammotoxin SIA, voltage-sensitive calcium channel responses, 451
- Neuropathy, peripheral, anti-HIV-1 therapy, PC12 cells, 702**
- Neurotensin, mimetics, pharmacological studies, dual effects as antagonist and agonist, 1036**
- Neurotransmitter, reconstitution of glutamate receptor proteins, artificial bilayers, *Xenopus* CNS, 142**
- NG108-15 cells**
 inhibition of potassium current, transfected D₂ short dopamine receptors, 649
 modification of G protein-coupled functions, low-pH pretreatment of membranes, 731
- Nitrendipine, modulation of NMDA receptor channel function, neurons (mouse), 443**
- Nitric oxide synthase**
 inhibitors, endothelial cell amino acid transport systems, 615
 regulation by nitric oxide (cattle), 124
- Noradrenalin-induced inositol phosphates, role of arachidonic acid and glutamate, striatal astrocytes, 1176**
- Nucleoside, transporters, inhibition of adenosine uptake, ethanol, 1021**
- O**
- Oligosaccharides, complex-type N-linked, β -funaltrexamine-labeled μ -opioid receptors, species differences (guinea pig, rat, mouse), 749**
- Oocytes, *Xenopus*, pore-forming P_{2U} purinoceptor, poly(A⁺) RNA from murine macrophages, 93**
- Opiates, alkaloids, agonist-induced state of δ -opioid receptor, 166**
- Opioids**
 agonist efficacy, G-protein-coupled functions, NG108-15 cells, 731
 μ , antisera against peptides, brain regions and cell line (cattle), 796
 nonpeptide, molecular mechanism of δ -selectivity, indole analogs, 1246
- Organophosphate, inhibition of fetal bovine serum acetylcholinesterase, modulation by monoclonal antibody AE-2, carbamate, 1152**
- P**
- Pancreas, α_2 -adrenergic receptor subtype distribution (human), 70**
- PC12 cells**
 anti-HIV-1 therapy, peripheral neuropathy, 702
 cyclic AMP elevation, multiple mechanisms, desensitization of A_{2A} adenosine receptor, 950
 intracellular calcium levels, ATP- and bradykinin-induced increases, chronic ethanol exposure, 405
- Peptides**
 α -amidation and peptidylglycine α -hydroxylating monooxygenase, control by disulfiram, 972
 derived from purified μ -opioid binding protein, antisera, brain regions and cell line (cattle), 796
 opioid, agonist-induced state, δ -opioid receptor, 166
 Peptidylglycine α -hydroxylating monooxygenase, peptide α -amidation and, control by disulfiram, 972
 Pertussis toxin, dual coupling in fibroblasts, cloned human 5-HT_{1D α} and 5-HT_{1D β} receptors (mouse), 575
- pH**
 -dependent inactivation, DT-diaphorase, mitomycin C and porfiro-mycin, 1128
 low, modification of G protein-coupled functions, NG108-15 cells, 731
- Phenobarbital-induced transcriptional activation, cytochrome P-450 genes, block by RU486 (rat), 775**
- Phenoxazines, N-substituted, reversal of *Vinca* alkaloid resistance, multidrug-resistant cancer cells, 552**
- Phenylalkylamine-binding polypeptide, σ_1 binding site, photoaffinity labeling and ligand-directed antibodies, 966**
- Phenylaminotetralins, σ -like receptor, ligand binding, functional studies, 1232**
- Phenylglyoxal, irreversible modification, red cell Ca²⁺ transport, 399**
- Phosphodiesterase, cyclic nucleotide isoforms, thymocyte proliferative response, cGMP-elevating agents, 1027**
- Phosphoinositide, functional role of M₂ muscarinic receptor, smooth muscle, ileum (guinea pig), 102**
- Phospholipase A₂, α -cobratoxin and, thymopoietin preparations, 678**
- N-(Phosphonacetyl)-L-aspartate, cytotoxicity of 5-fluorouracil/interferon- α -2a, colon cancer cell lines (human), 1070**
- Phosphoramidon, modulation of number of endothelin receptors, Swiss 3T3 fibroblasts, 422**
- 5-Phosphoribosyl-1-pyrophosphate synthetase, inhibition by 4-amino-8-(β -D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine (human, mouse), 479**
- Photoaffinity, labeling and ligand-directed antibodies, 27-kDa high affinity phenylalkylamine-binding polypeptide, 966**
- Physostigmine, block of ion channels, activation by acetylcholine, BC3H1 cells, 1051**
- Plasma membrane**
 secretory vesicle biogenic amine transporters, interactions, amphetamine derivatives, 1227
 synaptic, interaction, tricyclic drug analogs (rat), 129
- Poly(A⁺), RNA from murine macrophages, pore-forming P_{2U} purinoceptor, *Xenopus* oocytes, 93**
- Polymerase chain reaction, quantitative, 5-fluorouracil, altered dihydrofolate reductase pre-mRNA splicing (human), 22**
- Polypeptides, 27-kDa high affinity phenylalkylamine-binding, σ_1 binding site, 966**
- Pore, critical residue, barium blockade, clonal potassium channel, 180**
- Porfiro-mycin, pH-dependent inactivation, DT-diaphorase, 1128**
- Potassium channel**
 clonal, barium blockade, regulation of critical pore residue, 180
 cloned Kv1.2, α -dendrotoxin binding site interaction, tityustoxin-K α , 430
 delayed rectifier, terfenadine and its metabolites, heart (human), 1240
 rapidly activating delayed rectifier, block by verapamil, cloned from human heart, 642
 sulfonylurea-sensitive, novel subtype, modulation by dopamine (rat), 907
- Potassium current, inhibition, transfected D₂ short dopamine receptors, NG108-15 cells, 649**
- Pregnanolone, GABA_A receptor regulation (chick), 191**
- Proenkephalin, induction of sequential activation, metrazole, adrenal gland (rat), 328**
- Prostate, α_2 -adrenergic receptor subtype distribution (human), 70**
- Protein, CYP1A1 negative regulatory element, liver and hepatoma cells, 560**

Protein kinase

- calcium-dependent and -independent isozymes, ligand and substrate specificity (insect), 298
- cAMP-dependent
 - enhancement, GABA_A receptor currents, 1202
 - inhibition of Na-K-Cl cotransport, amiloride analogues, 393
- Protein kinase A, enkephalin gene transcription, DNase I-hypersensitive sites, chromaffin cells (cattle), 545
- Protein kinase C, indirect inhibition of cAMP generation, bradykinin, glomeruli and mesangial cells (rat), 818
- Purine, 2'- β -fluoro-2',3'-dideoxynucleosides, enhanced stimulation by ribavirin, 5'-phosphorylation and anti-HIV activity, 519
- Purinoreceptors, pore-forming P_{2z}, poly(A⁺) RNA from murine macrophages, *Xenopus* oocytes, 93
- Pyrazinones, substituted, interaction with GABA_A receptors, 468
- Pyruvate, anti-HIV-1 therapy, peripheral neuropathy, PC12 cells, 702

R

- Rana batesbeiana*, biochemical and immunochemical comparison, saxiphilin and transferrin, 742

Receptors

- acetylcholine, α -bungarotoxin, retina (chick), 1046
- acetylcholine muscarinic m₂ and m₃, agonist-induced down-regulation, mRNA and protein in cerebellar granule cells, 940
- adenosine A₁, G protein activation, brain membranes (cattle), 115
- adenosine A₂, molecular cloning and functional expression, tissue distribution (sheep), 524
- adenosine A_{2a}, multiple mechanisms, cAMP elevation in PC12 cells, 950
- Ah, cloning and expression of cDNA (human), 911
- angiotensin, isoform from turkey adrenal gland, pharmacological distinction from mammalian receptors, 1
- angiotensin II, expression in heart, *Xenopus laevis*, 277
- aryl hydrocarbon, nuclear translocator protein, dioxin action, 511
- bradykinin, mixed B₁ and B₂ pharmacological selectivity (mouse), 346
- cannabinoid, binding and analgesic activity, structure-activity relationships, 1008
- chimeric muscarinic, epitopes, allosteric interactions, 583
- dopamine, paradoxical regulation, transfected 293 cells, 371
- dopamine D1
 - identical D1A and D1B mRNAs, kidney and brain (opossum), 918
 - retina (goldfish), 1113
- dopamine D2, inhibition of potassium current, NG108-15 cells, 649
- endothelin
 - follicular membranes, *Xenopus* oocytes, 153
 - modulation of number by phosphoramidon, Swiss 3T3 fibroblasts, 422
 - subtype expression, saphenous vein (rabbit), 959
- endothelin type A, MMQ cells, 285
- GABA_A
 - enhancement of currents, activation of cAMP-dependent protein kinase, 1202
 - GABA-induced chloride currents, benzodiazepine site agonists, 866
 - interaction, substituted pyrazinones, 468
 - regulation, pregnanolone (chick), 191
 - role of β subunit, pharmacology (human), 1211
 - U-93631, GABA-induced chloride currents (rat), 860
- GABA_A α subunit, *t*-butylbicyclophosphoro[³⁵S]thionate binding, regional γ -aminobutyric acid sensitivity (human, rat), 87
- GABA_A/benzodiazepine, role of γ subunits (human), 437
- GABA_A and glycine, positive modulation, inhalation anesthetic isoflurane, 628
- glutamate
 - α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate, cyclothiazide and concanavalin A, 504

- diversity of mRNA expression, live hippocampal CA1 neurons (rat), 308
- diversity of subunit mRNA expression, live hippocampal CA1 neurons (rat), 308
- reconstitution of proteins into artificial bilayers, *Xenopus* CNS, 142
- glycine, extracellular disulfide loop motif, 198
- histamine H₂, activation model, 886
- 5-HT_{1C}, density and mRNA levels, choroid plexus epithelial cells (rat), 725
- 5-HT_{1D}, role of threonine 342 in helix 7, ligand binding, 882
- 5-HT_{1D α} and 5-HT_{1D β} , dual coupling, fibroblasts (mouse), 575
- inositol-1,4,5-trisphosphate, calcium mobilization, SH-SY5Y cells, 810
- insulin, heterogeneity in tissues, B29,B29'-suberoyl-insulin (rat), 271
- σ -like, recognition by phenylaminotetralins, ligand binding, 1232
- metabotropic glutamate, developmental changes, cerebellar granule cells, 981
- N-methyl-D-aspartate
 - discrimination of subtypes, ifenprodil (rat), 851
 - long-lasting modification of channel, sulfhydryl redox process (rat), 473
 - metabotropic glutamate receptors, developmental changes in cerebellar granule cells, 981
 - modulation of channel function by nitrendipine, neurons (mouse), 443
- muscarinic, blockers of cardiac function, benzoquinoid tyrosine kinase inhibitors (bullfrog), 595
- muscarinic acetylcholine, *Drosophila* nervous system, immunocytochemistry, 716
- muscarinic m1, stable allosteric binding, 1171
- muscarinic m2, functional role, smooth muscle of ileum (guinea pig), 102
- muscarinic m3, agonist-induced receptor down-regulation, carboxyl-terminal threonine residues (human), 1158
- neurokinin A NK-2, pharmacological characterization, baculovirus/Sf-21 insect cell system, 356
- neurokinin type 1, [³H]FK888, characterization (guinea pig), 539
- neuromedin B, antagonists, substituted somatostatin analogues (rat), 841
- nicotinic acetylcholine
 - interaction with curare, selective enhancement (mouse), 237
 - mapping ligand binding sites, chimeric α subunits, 657
 - volume- and length-dependent loss of activity, cycloalkanemethanols, 1219
- NMDA, agonist response kinetics, neurons (rat), 1252
- nonselective-type endothelin, alternative transcript, brain (rat), 533
- opioid
 - differential down- and up-regulation, buprenorphine (rat), 173
 - in situ* interactions with G_o, brain (rat), 62
- opioid δ
 - agonist-induced state, discrimination between opioid peptides and opiate alkaloids, 166
 - gene expression increase by ethanol, neuronal cell lines, 1119
- opioid δ and μ , interactive down-regulation, neuroblastoma SK-N-SH cells, 461
- opioid μ
 - antipeptide antibodies, brain regions and cell line (cattle), 796
 - β -funaltrexamine labeling, species variations (guinea pig, rat, mouse), 749
 - molecular cloning and functional expression, brain (rat), 8
 - purinergic P_{2u}, cytosolic Ca²⁺ and cAMP levels, protein kinase C and glioma cells (rat), 1185
 - ryanodine, Ca²⁺ release, chlorocresol, 1192
 - serotonin, molecular cloning, adenylate cyclase activation (mammal), 229
 - somatostatin SSTR4 and SSTR5 (human), 385

- somatostatin subtype 2
 aspartate mutation at residue 89, Na⁺ regulation (mouse), 380
 splice variant, coupling to adenylyl cyclase, 1016
 thromboxane A₂, point mutation in 7th hydrophobic domain, agonist and antagonist binding sites, 934
 vasamicol, ligand complexes, picomolar dissociation constants, 633
 Red blood cells, Ca²⁺ transport, irreversible modification, phenylglyoxal, 399
 Retina
 α -bungarotoxin-sensitive acetylcholine receptors (chick), 1046
 truncated dopamine D1 receptor, cloning and characterization (goldfish), 1113
 Retrovirus, Moloney murine leukemia virus, inhibition of replication, antiestrogens, 324
 Ribavirin, enhanced stimulation, 5'-phosphorylation and anti-HIV activity, purine 2'- β -fluoro-2',3'-dideoxynucleosides, 519
 RNA
 α_2 -adrenergic receptor subtype distribution (human), 70
 poly(A⁺), pore-forming P_{2Z} purinoceptor, *Xenopus* oocytes, 93
 RNA, messenger
 alterations in dihydrofolate reductase pre-mRNA splicing, 5-fluorouracil, quantitative PCR (human), 22
 epoxide hydrolase, distribution and modulation, cytochrome P-450 (rat), 990
 glutamate receptor, diversity of expression, live hippocampal CA1 neurons (rat), 308
 5-HT_{1C} receptor density and, choroid plexus epithelial cells, mianserin and 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane treatment (rat), 725
 5-HT_{1D α} , expression in arteries (human, cattle), 242
 m₂- and m₃-muscarinic acetylcholine receptor, agonist-induced down-regulation, cerebellar granule cells, 940
 P4502C7, growth hormone and vitamin A, primary hepatocytes (rat), 997
 RP-60475, *see* Introplicine
 RU486, block, phenobarbital-induced transcriptional activation, cytochrome P-450 genes (rat), 775
 Ryanodine
 natural congeners, activating and deactivating effects, calcium release channel of sarcoplasmic reticulum (rabbit), 412
 receptor-mediated Ca²⁺ release, activator, chlorocresol, 1192

S

- Sarcoplasmic reticulum, activating and deactivating effects, calcium release channel, natural ryanodine congeners (rabbit), 412
 Saxiphilin, transferrin and, biochemical and immunochemical comparison, *Rana catesbeiana*, 742
 Seizures, GABA_A receptor regulation, pregnanolone (chick), 191
 Selenium, deficiency, electron spin resonance, free radical generation (rat), 222
 Serotonin, molecular cloning of receptor, adenylate cyclase activation (mammal), 229
 SH-SY5Y cells, calcium mobilization via the inositol-1,4,5-trisphosphate receptor, induction by inositol-1,3,4,5-tetrakisphosphate, 810
 Signal transduction
 comparison of α_1 -adrenergic receptor subtypes, neuronal cell lines, 76
 endothelin receptors, follicular membranes, *Xenopus* oocytes, 153
 multiple pathways, coupling of α_{1B} and α_{1D} -adrenergic receptors, G protein and cell type specific, 784
 structural and conformational features, *beta*-3 adrenoreceptors, 1094
 SK-MG-1 cells, transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea, mediation, epinephrine-sensitive carrier system, 204
 SK-N-MC cells, comparison of α_1 -adrenergic receptor subtypes, signal transduction, 76

- SK-N-SH cells, interactive down-regulation, μ - and δ -opioid receptors, 461
 Sodium, regulation of agonist binding, aspartate mutation at residue 89, somatostatin receptor subtype 2 (mouse), 380
 Sodium channels, batrachotoxin-modified, quaternary ammonium blockers, 667
 Sodium-potassium-chloride, inhibition of cotransport, amiloride analogues, stimulation of cyclic AMP-dependent protein kinase, 393
 Somatostatin analogues, substituted, neuromedin B receptor antagonists (rat), 841
 Species differences, β -funaltrexamine labeling, μ -opioid receptors, complex-type N-linked oligosaccharides (guinea pig, rat, mouse), 749
 Spleen, α_2 -adrenergic receptor subtype distribution (human), 70
 Spongistatin 1, inhibition of mitosis and microtubule assembly, binding of vinblastine to tubulin (sponge), 757
 Steroids
 anesthetic, role of cytochrome P450 in regulation, brain (rat), 1077
 GABA_A receptor regulation, pregnanolone (chick), 191
 role of β subunit, pharmacology, GABA_A receptors (human), 1211
 Stomach, α_2 -adrenergic receptor subtype distribution (human), 70
Streptoalloteichus hindustanus, nuclear localization, bleomycin resistance protein, mammalian cells, 1135
 Substrate, specificity and ligands, calcium, protein kinase isozymes (insect), 298
 Sulfhydryl, voltage-dependent redox process, long-lasting modification, NMDA receptor channel (rat), 473
 Sulfonyleurea-sensitive potassium channels, novel subtype, modulation by dopamine (rat), 907
 Sumatriptan, cloned human 5-HT_{1D α} and 5-HT_{1D β} , dual coupling, fibroblasts (mouse), 575
 Synapse, plasma membranes, interaction, tricyclic drug analogs (rat), 129

T

- Tamoxifen, inhibition of replication, retroviral Moloney murine leukemia virus, 324
 Terfenadine, its metabolites and, delayed rectifier K⁺ channel, heart (human), 1240
 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
 binding in liver, interactions, indolol[3,2-*b*]carbazoles and related polycyclic aromatic hydrocarbons (rat), 336
 cardiac myocyte intracellular calcium, impaired ventricular contractile responses, isoproterenol and calcium (chick), 1142
 Threonine, residues, m3 muscarinic acetylcholine, agonist-induced down-regulation (human), 1158
 Threonine 342, role in helix 7, 5-HT_{1D} receptor, ligand binding, 882
 Thromboxane, A₂ receptor, point mutation, 7th hydrophobic domain, 934
 Thymidine kinase, phosphorylation of enantiomers, carbocyclic analog of 2'-deoxyguanosine, HSV-1 and uninfected cells, 1258
 Thymidylate synthase, naturally occurring amino acid substitution, functional effects (human), 316
 Thymocytes, modulation of proliferative response, inhibition of cyclic nucleotide phosphodiesterase isoforms, cGMP-elevating agents, 1027
 Thymopoietin, preparations, α -cobratoxin and phospholipase A₂ activity, 678
 Tityustoxin-K α , interaction with α -dendrotoxin binding site, cloned Kv1.2 K⁺ channel, 430
 m1-Toxin, stable allosteric binding, m1 muscarinic receptors, 1171
 Transferrin
 endocytosis and exocytosis, antimycin A, β -adrenergic receptors (human), 364
 saxiphilin and, biochemical and immunochemical comparison, *Rana catesbeiana*, 742
 Tricyclic drug analogs, interaction with synaptic plasma membranes (rat), 129

- Trimetrexate, mutations leading to antifolate resistance, ethylmethanesulfonate exposure, CHO cells, 13
- d*-Tubocurarine, see Curare
- Tubulin, binding of vinblastine, spongistatin 1, inhibition of mitosis (sponge), 757
- Tyrosine hydroxylase, gene expression, metrazole, adrenal gland (rat), 328
- Tyrosine kinase, inhibitors, blockers of cardiac muscarinic receptor function (bullfrog), 595

U

- U-93631, rapid decay of GABA-induced chloride currents, recombinant GABA_A receptors (rat), 860
- Uridine, anti-HIV-1 therapy, peripheral neuropathy, PC12 cells, 702

V

- Vein, saphenous, expression, endothelin receptor subtypes (rabbit), 959
- Vena cava, α_2 -adrenergic receptor subtype distribution (human), 70
- Verapamil, block of rapidly activating delayed rectifier K⁺ channel, cloned from human heart, 642
- Vesamicol, receptor-ligand complexes, picomolar dissociation constants, kinetic and equilibrium characterization, 633

- Vesicles, secretory, biogenic amine transporters and plasma membrane interaction, amphetamine derivatives, 1227
- Vinblastine, binding to tubulin, spongistatin 1, inhibition of mitosis (sponge), 757
- Vinca, alkaloid resistance, reversal by *N*-substituted phenoxazines, multidrug-resistant cancer cells, 552
- Vitamin A, growth hormone and, induction of P4502C7 mRNA, primary hepatocytes (rat), 997
- Vitamin E, deficiency, electron spin resonance, free radical generation (rat), 222

W

- WI-L2 cells, inhibition of 5-phosphoribosyl-1-pyrophosphate synthetase, 4-amino-8-(β -D-ribofuranosylamino)pyrimido [5,4-*d*]pyrimidine (human, mouse), 479

X

- Xenopus laevis*, angiotensin II receptor expression, heart, 277

Z

- Zinc, inhibition of flux, benzodiazepine-insensitive GABA chloride channels, cortical and cerebellar microsacs (rat), 876
- Zonisamide, reductive metabolism, liver microsomal cytochrome P450 (human), 216

AUTHOR INDEX FOR VOLUME 44

A

- Abdel-Razzak, Z., Loyer, P., Fautrel, A., Gautier, J.-C., Corcos, L., Turlin, B., Beaune, P., and Guillouzo, A. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture, 707
- Abel, P. W., *see* Feng, F., 926
- Abutidze, K., *see* Kerry, C. J., 142
- Adams, M. E., Mintz, I. M., Reily, M. D., Thanabal, V., and Bean, B. P. Structure and properties of ω -agatoxin IVB, a new antagonist of P-type calcium channels, 681
- Adenik, M., *see* Shaw, P. M., 775
- Afar, R., *see* Quik, M., 680
- Agbunag, R. V., *see* Probst, M. R., 511
- Aguayo, L., *see* Li, C., 871
- Aharony, D., Little, J., Powell, S., Hopkins, B., Bundell, K. R., McPheat, W. L., Gordon, R. D., Hassall, G., Hockney, R., Griffin, R., and Graham, A. Pharmacological characterization of cloned human NK-2 (neurokinin A) receptor expressed in a baculovirus/Sf-21 insect cell system, 356
- Ahluwalia, G. S., *see* Johns, D. G., 519
- Aiyar, N., *see* Bergama, D. J., 277
- Aizenman, E., *see* Tang, L.-H., 473
- Alexander, R. W., *see* Murphy, T. J., 1
- Alexandersson, M., *see* Gillner, M., 336
- Allan, P. W., *see* Bennett, L. L., Jr., 1258
- Amlaiki, N., *see* Plassat, J.-L., 229
- Anand, R., Peng, X., Ballesta, J. J., and Lindstrom, J. Pharmacological characterization of α -bungarotoxin-sensitive acetylcholine receptors immunisolated from chick retina: Contrasting properties of $\alpha 7$ and $\alpha 8$ subunit-containing subtypes, 1046
- Anderson, R., Smit, M. J., and Van Rensburg, C. E. J. Lysophospholipid-mediated inhibition of Na^+, K^+ -adenosine triphosphatase is a possible mechanism of immunosuppressive activity of cyclosporin A, 605
- Angelotti, T. P., Uhler, M. D., and MacDonald, R. L. Enhancement of recombinant γ -aminobutyric acid type A receptor currents by chronic activation of cAMP-dependent protein kinase, 1202
- Anthony, N. M., *see* Blake, A. D., 716
- Applegren, N., *see* Bachur, N. R., 1064
- Arai, H., *see* Siegel, D., 1128
- Areces, L. B., *see* Kazanietz, M. G., 298
- Armstrong, S. G., and Renton, K. W. Mechanism of hepatic cytochrome P450 modulation during *Listeria monocytogenes* infection in mice, 677
- Arnett, G., *see* Bennett, L. L., Jr., 1258
- Aronica, E., Dell'Albani, P., Condorelli, D. F., Nicoletti, F., Hack, N., and Balázs, R. Mechanisms underlying developmental changes in the expression of metabotropic glutamate receptors in cultured cerebellar granule cells: Homologous desensitization and interactive effects involving N-methyl-D-aspartate receptors, 981
- Artymyshyn, R. P., *see* Boundy, V. A., 677
- Artymyshyn, R. P., *see* Filtz, T. M., 371
- Audhya, T., *see* Lukas, R. J., 680
- Audhya, T., *see* Quik, M., 680
- Aylwin, M. L., *see* Filatov, G. N., 237

B

- Baba, M., *see* Yuasa, S., 895
- Bachur, N. R., Johnson, R., Yu, F., Hickey, R., Applegren, N., and

- Malkas, L. Antihelicase action of DNA-binding anticancer agents: Relationship to guanosine-cytidine intercalator binding, 1064
- Bahador, A., *see* Kazanietz, M. G., 298
- Bai, R., Cichacz, Z. A., Herald, C. L., Pettit, G. R., and Hamel, E. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin, 757
- Bain, C., *see* Hadingham, K. L., 1211
- Bain, C. J., *see* Wafford, K. A., 437
- Bajaj, R., *see* Wadler, S., 1070
- Baker, S. A., *see* Thomas, E. A., 102
- Balázs, R., *see* Aronica, E., 981
- Baldessarini, R. J., *see* Booth, R. G., 1232
- Ballesta, J. J., *see* Anand, R., 1046
- Balzarini, J., Karlsson, A., and De Clercq, E. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives, 694
- Banerjee, D., *see* Fanin, R., 13
- Banner, C. D., *see* Strömstedt, M., 1077
- Barbour, K. W., *see* Hughey, C. T., 316
- Barg, J., *see* Belcheva, M. M., 173
- Barker, E. L., and Sanders-Buch, E. 5-Hydroxytryptamine_{1C} receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane, 725
- Barnard, E. A., *see* Kerry, C. J., 142
- Barnes, P. J., *see* Miyayasu, K., 539
- Barry, P. H., *see* Vandenberg, R. J., 198
- Bascands, J.-L., Pecher, C., and Girolami, J.-P. Indirect inhibition by bradykinin of cyclic AMP generation in isolated rat glomeruli and mesangial cells, 818
- Batley, J. F., *see* Orbach, M., 841
- Baumhaker, Y., Gafni, M., Keren, O., and Sarne, Y. Selective and interactive down-regulation of μ - and δ -opioid receptors in human neuroblastoma SK-N-SH cells, 461
- Bayard, F., *see* Chailleux, C., 324
- Beall, H., *see* Siegel, D., 1128
- Bean, B. P., *see* Adams, M. E., 681
- Beatty, M. F., *see* Maguire, P. A., 1246
- Beaumont, K., Kenney, M. A., Young, A. A., and Rink, T. J. High affinity amylin binding sites in rat brain, 493
- Beaune, P., *see* Abdel-Razzak, Z., 707
- Becker, W., *see* Breiner, M., 271
- Begleiter, A., and Leith, M. K. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under acidic conditions, 210
- Belcheva, M. M., Barg, J., McHale, R. J., Dawn, S., Ho, M. T., Ignatova, E., and Coscia, C. J. Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine, 173
- Bell, D., *see* Wang, G. K., 667
- Bell, G. I., *see* Kong, H., 380
- Bell, G. I., *see* Raynor, K., 385
- Bell, G. I., *see* Reisine, T., 1016
- Bennett, L. L., Jr., Parker, W. B., Allan, P. W., Rose, L. M., Shealy, Y. F., Secrist, J. A., III, Montgomery, J. A., Arnett, G., Kirkman, R. L., and Shannon, W. M. Phosphorylation of the enantiomers of the carbocyclic analog of 2'-deoxyguanosine in cells infected with herpes simplex virus type 1 and in uninfected cells. Lack of enantiomeric selectivity with the viral thymidine kinase, 1258
- Berger, F. G., *see* Hughey, C. T., 316

- Berger, S. H., *see* Hughey, C. T., 316
 Bergman, J., *see* Gillner, M., 336
 Bergama, D. J., Ellis, C., Nuthulaganti, P. R., Nambi, P., Scaife, K., Kumar, C., and Aiyar, N. Isolation and expression of a novel angiotensin II receptor from *Xenopus laevis* heart, 277
 Bertino, J. R., *see* Fanin, R., 13
 Beach, H. R., Jr., *see* Humerickhouse, R. A., 412
 Bijsterbosch, M. K., *see* Schouten, D., 486
 Blake, A. D., Anthony, N. M., Chen, H. H., Harrison, J. B., Nathanson, N. M., and Sattelle, D. B. *Drosophila* nervous system muscarinic acetylcholine receptor: Transient functional expression and localization by immunocytochemistry, 716
 Blanck, T. J. J., *see* Canga, L., 1142
 Blaustein, M. P., *see* Werkman, T. R., 430
 Blin, N., Camoin, L., Maigret, B., and Strosberg, A. D. Structural and conformational features determining selective signal transduction in the $\beta 3$ -adrenergic receptor, 1094
 Blumberg, P. M., *see* Kazanietz, M. G., 298
 Booth, R. G., Wyrick, S. D., Baldessarini, R. J., Kula, N. S., Myers, A. M., and Mailman, R. B. New σ -like receptor recognized by novel phenylaminotetralins: Ligand binding and functional studies, 1232
 Borden, L. A., *see* Zgombick, J. M., 575
 Boritzki, T. J., *see* Fry, D. W., 479
 Boundy, V. A., Luedtke, R. R., Artymyshyn, R. P., Filtz, T. M., and Molinoff, P. B. Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides, 677
 Bradfield, C. A., *see* Dolwick, K. M., 911
 Bradford, P. G., Jin, Y., and Hui, P. 1,25-Dihydroxyvitamin D₃ enhances the transcription and expression of the inositol trisphosphate receptor gene in HL-60 cells, 292
 Branchek, T. A., *see* Michel, M. D., 1165
 Branchek, T. A., *see* Zgombick, J. M., 575
 Brann, M. R., *see* Ellis, J., 583
 Breiner, M., Weiland, M., Becker, W., Müller-Weiland, D., Streicher, R., Fabry, M., and Joost, H. G. Heterogeneity of insulin receptors in rat tissues as detected with the partial agonist B29,B29'-suberoyl-insulin, 271
 Breivogel, C. S., *see* Selley, D. E., 731
 Bresnick, E., *see* Sterling, K., 560
 Brett, R. S., *see* Dilger, J. P., 1056
 Brodsky, M., *see* Zhu, Y.-S., 328
 Brooker, G., *see* Munshi, R., 1185
 Brown, A. M., *see* Rampe, D., 642, 1240
 Brown, A. M., *see* Taghialatela, M., 180
 Brown, M., *see* McIntyre, P., 346
 Buckpitt, A. R., *see* Plopper, C. G., 51
 Bundell, K. R., *see* Aharony, D., 356
 Burrows, G. G., *see* Moebius, F. F., 966
 Butcher, R. W., *see* Proll, M. A., 569
- C
- Calmels, T. P. G., Mistry, J. S., Watkins, S. C., Robbins, P. D., McGuire, R., and Lazo, J. S. Nuclear localization of bacterial *Streptococcus hindustanus* bleomycin resistance protein in mammalian cells, 1135
 Cambillau, C., *see* Gillner, M., 336
 Camoin, L., *see* Blin, N., 1094
 Canga, L., Paroli, L., Blanck, T. J. J., Silver, R. B., and Rifkind, A. B. 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin increases cardiac myocyte intracellular calcium and progressively impairs ventricular contractile responses to isoproterenol and to calcium in chick embryo hearts, 1142
 Carfagna, M. A., and Muhoherac, B. B. Interaction of tricyclic drug analogs with synaptic plasma membranes: structure-mechanism relationships in inhibition of neuronal Na⁺/K⁺-ATPase activity, 129
 Caron, M. G., *see* Nash, S. R., 918
 Carr, C., *see* Georgoussi, Z., 62
 Carter, D. B., *see* Dillon, G. H., 860
 Carter, D. B., *see* Im, H. K., 468, 866
 Carver, L. A., *see* Dolwick, K. M., 911
 Castellano, M. A., Liu, L.-X., Monsma, F. J., Jr., Sibley, D. R., Kapatos, G., and Chiodo, L. A. Transfected D₂ short dopamine receptors inhibit voltage-dependent potassium current in neuroblastoma × glioma hybrid (NG108-15) cells, 649
 Casy, A. F., *see* Maguire, P. A., 1246
 Chailleux, C., Mesange, F., Bayard, F., Prats, A.-C., and Faye, J.-C. Antiestrogens inhibit the replication of the retroviral Moloney murine leukemia virus *in vitro*, 324
 Challias, R. A. J., *see* Wilcox, R. A., 810
 Chang, A., *see* Plopper, C. G., 51
 Chang, K.-J., *see* Cheng, H.-F., 533
 Chang, K.-J., *see* Childers, S. R., 827
 Changeux, J.-P., *see* Quik, M., 678
 Chao, C.-C., *see* Webb, M. L., 959
 Charness, M. E., Hu, G., Edwards, R. H., and Querimit, L. A. Ethanol increases δ -opioid receptor gene expression in neuronal cell lines, 1119
 Chaudhry, A., *see* Granneman, J. G., 264
 Chen, C., *see* Liu-Chen, L.-Y., 749
 Chen, H. H., *see* Blake, A. D., 716
 Chen, R., *see* Westin, S., 997
 Chen, Y., Mestek, A., Liu, J., Hurley, J. A., and Yu, L. Molecular cloning and functional expression of a μ -opioid receptor from rat brain, 8
 Cheng, H.-F., Su, Y.-M., Yeh, J.-R., and Chang, K.-J. Alternative transcript of nonselective-type endothelin receptor from rat brain, 533
 Chern, Y., Lai, H.-L., Fong, J. C., and Liang, Y. Multiple mechanisms for desensitization of A2a adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells, 950
 Chia, L.-S., *see* Hamel, E., 242
 Chiang, P. K., *see* Wolfe, A. D., 1152
 Childers, S. R., Fleming, L. M., Selley, D. E., McNutt, R. W., and Chang, K.-J. BW373U86: A nonpeptidic δ -opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cells, 827
 Childers, S. R., *see* Selley, D. E., 731
 Chiodo, L. A., *see* Castellano, M. A., 649
 Chiou, W., *see* Wu-Wong, J. R., 285
 Chiou, W. J., *see* Wu-Wong, J. R., 422
 Chuang, D.-M., *see* Fukamauchi, F., 940
 Chuang, D.-M., *see* Lin, W.-W., 158
 Cichacz, Z. A., *see* Bai, R., 757
 Clark, R. B., *see* Proll, M. A., 569
 Clementi, E., *see* Zorzato, F., 1192
 Cochran, T. L., *see* Zgombick, J. M., 575
 Condorelli, D. F., *see* Aronica, E., 981
 Cook, P. D., *see* Fry, D. W., 479
 Cook, R. G., *see* Quik, M., 678
 Cooney, D. A., *see* Johns, D. G., 519
 Corcos, L., *see* Abdel-Razzak, Z., 707
 Corcos, L., *see* Shaw, P. M., 775
 Cordier, J., *see* Marin, P., 1176
 Coscia, C. J., *see* Belcheva, M. M., 173
 Counillon, L., Scholz, W., Lang, H. J., and Pouyssegur, J. Pharmacological characterization of stably transfected Na⁺/H⁺ antiporter isoforms using amiloride analogs and a new inhibitor exhibiting anti-ischemic properties, 1041
 Coy, D. H., *see* Orbuch, M., 841
 Cusack, B., Richelson, E., Pang, Y.-P., Zaidi, J., and Kozikowski, A. P. Pharmacological studies on novel neurotensin mimetics: Discovery of a pharmacologically unique agent exhibiting concentration-dependent dual effects as antagonist and agonist, 1036

D

- Dage, R. C., *see* Rampe, D., 642, 1240
Davies, M. F., Maguire, P. A., and Loew, G. H. Zinc selectively inhibits flux through benzodiazepine-insensitive γ -aminobutyric acid chloride channels in cortical and cerebellar microsacs, 876
Davison, M. D., *see* Lampe, R. A., 451
Dawn, S., *see* Belcheva, M. M., 173
DeBernardi, M. A., *see* Munshi, R., 1185
De Clercq, E., *see* Balzarini, J., 694
De Clercq, E., *see* Jansen, R. W., 1003
DeFeo, P. A., *see* Lampe, R. A., 451
Dell'Albani, P., *see* Aronica, E., 981
de S. Otero, A., and Sweitzer, N. M. Benzoquinoid tyrosine kinase inhibitors are potent blockers of cardiac muscarinic receptor function, 595
Devane, W. A., *see* Mackie, K., 498
DeYoung, M. B., *see* Perez, D. M., 784
Diamond, I., *see* Krauss, S. W., 1021
Dicker, A. P., *see* Fanin, R., 13
Dilger, J. P., Brett, R. S., and Mody, H. I. The effects of isoflurane on acetylcholine receptor channels: 2. Currents elicited by rapid perfusion of acetylcholine, 1056
Dillon, G. H., Im, H. K., Hamilton, B. J., Carter, D. B., Gammill, R. B., Judge, T. M., and Im, W. B. U-93631 causes rapid decay of γ -aminobutyric acid-induced chloride currents in recombinant rat γ -aminobutyric acid type A receptors, 860
Dixon, S. J., *see* Feldman, R. D., 393
Doctor, B. P., *see* Wolfe, A. D., 1152
Dolnick, B. J., *see* Wu, X.-P., 22
Dolwick, K. M., Schmidt, J. V., Carver, L. A., Swanson, H. I., and Bradfield, C. A. Cloning and expression of a human Ah receptor cDNA, 911
Drewe, J. A., *see* Tagliatela, M., 180
Driscoll, J. S., *see* Johns, D. G., 519
Dubyak, G. R., *see* Nuttle, L. C., 93

E

- Eason, M. G., and Liggett, S. B. Human α_2 -adrenergic receptor subtype distribution: widespread and subtype-selective expression of α_2C10 , α_2C4 , and α_2C2 mRNA in multiple tissues, 70
Eberwine, J. H., *see* Mackler, S. A., 308
Edwards, R. H., *see* Charness, M. E., 1119
Ehlert, F. J., *see* Thomas, E. A., 102
Eiden, L. E., *see* MacArthur, L., 545
Eipper, B. A., *see* Mueller, G. P., 972
El-Bizri, H., *see* Quik, M., 680
Ellis, C., *see* Bergsma, D. J., 277
Ellis, J., Seidenberg, M., and Brann, M. R. Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions, 583
El-Moatassim, C., *see* Nuttle, L. C., 93
Emmick, J. T., *see* Humerickhouse, R. A., 412
Eriks, J. C., Van der Goot, H., and Timmerman, H. New activation model for the histamine H_2 receptor, explaining the activity of the different classes of histamine H_2 receptor agonists, 886
Ebenshade, T. A., Han, C., Murphy, T. J., and Minneman, K. P. Comparison of α_1 -adrenergic receptor subtypes and signal transduction in SK-N-MC and NB41A3 neuronal cell lines, 76
Evans, C. J., *see* Von Zastrow, M., 166

F

- Fabry, M., *see* Breiner, M., 271
Fan, E., *see* Hamel, E., 242
Fanin, R., Banerjee, D., Volkenandt, M., Waltham, M., Li, W. W., Dicker, A. P., Schweitzer, B. I., and Bertino, J. R. Mutations leading to antifolate resistance in Chinese hamster ovary cells after exposure to the alkylating agent ethylmethanesulfonate, 13

- Farb, D. H., *see* Friedman, L., 191
Fautrel, A., *see* Abdel-Razzak, Z., 707
Faye, J.-C., *see* Chailleux, C., 324
Fedida, D., *see* Rampe, D., 642
Feldman, R. D., and Dixon, S. J. Inhibition of NA-K-C cotransport by amiloride analogues is associated with stimulation of cyclic AMP-dependent protein kinase, 393
Feng, F., Abel, P. W., Scofield, M., Liu, F., Wolff, D. W., and Jeffries, W. B. Heterogeneous expression of α_1 -adrenoceptor subtypes among rat nephron segments, 926
Fernström, B., *see* Gillner, M., 336
Filatov, G. N., Aylwin, M. L., and White, M. M. Selective enhancement of the interaction of curare with the nicotinic acetylcholine receptor, 237
Filtz, T. M., Artymyshyn, R. P., Guan, W., and Molinoff, P. B. Paradoxical regulation of dopamine receptors in transfected 293 cells, 371
Filtz, T. M., *see* Boundy, V. A., 677
Fink, J. S., *see* Linden, J., 524
Fisher, S. M., *see* Webb, M. L., 959
Fitzgerald, G. A., *see* Funk, C. D., 934
Fleming, L. M., *see* Childers, S. R., 827
Fong, J. C., *see* Chern, Y., 950
Forray, C., *see* Michel, M. D., 1165
Frail, D. E., Manelli, A. M., Witte, D. G., Lin, C. W., Steffey, M. E., and MacKenzie, R. G. Cloning and characterization of a truncated dopamine D1 receptor from goldfish retina: Stimulation of cyclic AMP production and calcium mobilization, 1113
Franklin, S. O., *see* Zhu, Y.-S., 328
Freedman, J. E., *see* Lin, Y.-J., 907
French, C. R., *see* Vandenberg, R. J., 198
Fridland, A., *see* Gong, Y.-F., 30
Friedman, L., Gibbs, T. T., and Farb, D. H. γ -Aminobutyric acid, receptor regulation: chronic treatment with pregnanolone uncouples allosteric interactions between steroid and benzodiazepine recognition sites, 191
Fry, D. W., Boritzki, T. J., Jackson, R. C., Cook, P. D., and Leopold, W. R. Inhibition of 5-phosphoribosyl-1-pyrophosphate synthetase by the monophosphate metabolite of 4-amino-8-(β -D-ribofuranosylamino)pyrimido-[5,4-d] pyrimidine: A novel mechanism for antitumor activity, 479
Fryar, N., *see* Wolfe, A. D., 1152
Fukamauchi, F., Saunders, P. A., Hough, C., and Chuang, D.-M. Agonist-induced down-regulation and antagonist-induced up-regulation of m_2 - and m_3 -muscarinic acetylcholine receptor mRNA and protein in cultured cerebellar granule cells, 940
Funk, C. D., Furci, L., Moran, N., and Fitzgerald, G. A. Point mutation in the seventh hydrophobic domain of the human thromboxane A_2 receptor allows discrimination between agonist and antagonist binding sites, 934
Furci, L., *see* Funk, C. D., 934
Fuss, M., *see* Lorenzen, A., 115

G

- Gafni, M., *see* Baumhaker, Y., 461
Gammill, R. B., *see* Dillon, G. H., 860
Gammill, R. B., *see* Im, H. K., 468
García-Sáinz, J. A., and Romero-Avila, M. T. Characterization of the α_{1A} -adrenoceptors of guinea pig liver membranes: Studies using 5-[3H] methylurapidil, 589
Gautier, J.-C., *see* Abdel-Razzak, Z., 707
Geertsen, S., *see* Quik, M., 680
Georgousi, Z., Carr, C., and Milligan, G. Direct measurements of *in situ* interactions of rat brain opioid receptors with the guanine nucleotide-binding protein G_o , 62
Gerzon, K., *see* Humerickhouse, R. A., 412
Ghirnikar, R. B., *see* Krauss, S. W., 1021

- Gibbs, T. T., *see* Friedman, L., 191
 Gibson, N. W., *see* Siegel, D., 1128
 Gillner, M., Bergman, J., Cambillau, C., Alexandersson, M., Fernström, B., and Gustafsson, J.-A. Interactions of indolo[3,2-*b*]carbazoles and related polycyclic aromatic hydrocarbons with specific binding sites for 2,3,7,8-tetrachlorodibenzo-*p*-dioxin in rat liver, 336
 Giannini, T. L., Yao, Y. H., Miller, J. M., Taylor, L. P., and Simon, E. J. Antisera against peptides derived from a purified μ -opioid binding protein recognize the protein as well as μ -opioid receptors in brain regions and a cell line, 796
 Girolami, J.-P., *see* Bascanda, J.-L., 818
 Glossman, H., *see* Moebius, F. F., 966
 Glowinski, J., *see* Marin, P., 1176
 Godinot, N., *see* Nash, S. R., 918
 Goepfert, A. R., Te Koppele, J. M., Lamme, E. K., Piqué, J. M., and Vermeulen, N. P. E. Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: A study with rat liver microsomes and purified enzymes, 1267
 Goldstein, G., *see* Lukas, R. J., 680
 Goldstein, G., *see* Quik, M., 680
 Gong, Y.-F., Srinivas, R. V., and Fridland, A. 5-Amino-4-imidazolecarboxamide riboside potentiates the metabolism and anti-human immunodeficiency virus activity of 2',3'-dideoxyinosine, 30
 Goodnight, J., *see* Kazanietz, M. G., 298
 Gordon, A. S., *see* Krauss, S. W., 1021
 Gordon, R. D., *see* Aharony, D., 356
 Graham, A., *see* Aharony, D., 356
 Graham, R. M., *see* Perez, D. M., 784
 Granneman, J. G., Lahners, K. N., and Chaudhry, A. Characterization of the human β_2 -adrenergic receptor gene, 264
 Green, R. D., *see* Yu, H. J., 689
 Greenblatt, E. P., *see* Harrison, N. L., 628
 Greif, G. J., *see* Lin, Y.-J., 907
 Griffin, R., *see* Aharony, D., 356
 Guan, W., *see* Filtz, T. M., 371
 Guillouzo, A., *see* Abdel-Razzak, Z., 707
 Gustafson, T. A., *see* Werkman, T. R., 430
 Gustafsson, J.-A., *see* Gillner, M., 336
 Gustafsson, J.-A., *see* Strömstedt, M., 1077
 Gustafsson, J.-A., *see* Westin, S., 997
- H**
- Hack, N., *see* Aronica, E., 981
 Hadingham, K. L., Wingrove, P. B., Wafford, K. A., Bain, C., Kemp, J. A., Palmer, K. J., Wilson, A. W., Wilcox, A. S., Sikela, J. M., Ragan, C. I., and Whiting, P. J. Role of the β subunit in determining the pharmacology of human γ -aminobutyric acid type A receptors, 1211
 Hallam, S., *see* Wadler, S., 1070
 Hamel, E., Fan, E., Linville, D., Ting, V., Villemure, J.-G., and Chia, L.-S. Expression of mRNA for the serotonin 5-hydroxytryptamine_{1D}[cf10] β [cf1] receptor subtype in human and bovine cerebral arteries, 242
 Hamel, E., *see* Bai, R., 757
 Hamilton, B. J., *see* Dillon, G. H., 860
 Hamilton, B. J., *see* Im, H. K., 468, 866
 Han, C., *see* Esbenshade, T. A., 76
 Hand, K., *see* Rogers, G. A., 633
 Hankinson, O., *see* Probst, M. R., 511
 Hanna, P. M., *see* Kadiiska, M. B., 222
 Hanner, M., *see* Moebius, F. F., 966
 Harrison, J. B., *see* Blake, A. D., 716
 Harrison, N. L., Kugler, J. L., Jones, M. V., Greenblatt, E. P., and Pritchett, D. B. Positive modulation of human γ -aminobutyric acid type A and glycine receptors by the inhalation anesthetic isoflurane, 628
 Harwood, F. C., *see* Horton, J. K., 552
 Hassall, G., *see* Aharony, D., 356
 Hawthorn, M., *see* Kim, W.-K., 405
 Hen, R., *see* Plassat, J.-L., 229
 Herald, C. L., *see* Bai, R., 757
 Herman, J. L., *see* Lampe, R. A., 451
 Hickey, R., *see* Bachur, N. R., 1064
 Hill, W. A., *see* Wood, S. C., 1219
 Hille, B., *see* Mackie, K., 498
 Ho, K. L., *see* Sterling, K., 560
 Ho, M. T., *see* Belcheva, M. M., 173
 Hobbs, G. A., *see* Keilbaugh, S. A., 702
 Hockney, R., *see* Aharony, D., 356
 Hoffman, B. B., *see* Hu, Z.-W., 1105
 Hopkins, B., *see* Aharony, D., 356
 Horn, M. B., *see* Lampe, R. A., 451
 Horton, J. K., Thimmaiah, K. N., Harwood, F. C., Kuttasch, J. F., and Houghton, P. J. Pharmacological characterization of *N*-substituted phenoxazines directed toward reversing *vinca* alkaloid resistance in multidrug-resistant cancer cells, 552
 Hough, C., *see* Fukamauchi, F., 940
 Houghton, P. J., *see* Horton, J. K., 552
 Howlett, A. C., *see* Melvin, L. S., 1008
 Hu, G., *see* Charness, M. E., 1119
 Hu, Z.-W., and Hoffman, B. B. Cycloheximide induces the α_{1B} adrenergic receptor gene by activation of transcription in DDT₁ MF-2 smooth muscle cells, 1105
 Huang, T., *see* Zhu, Y.-S., 328
 Hughey, C. T., Barbour, K. W., Berger, F. G., and Berger, S. H. Functional effects of a naturally occurring amino acid substitution in human thymidylate synthase, 316
 Hui, P., *see* Bradford, P. G., 292
 Humerickhouse, R. A., Besch, H. R., Jr., Gerzon, K., Ruest, L., Sutko, J. L., and Emmick, J. T. Differential activating and deactivating effects of natural ryanodine congeners on the calcium release channel of sarcoplasmic reticulum: Evidence for separation of effects at functionally distinct sites, 412
 Hurley, J. A., *see* Chen, Y., 8
 Husten, E. J., *see* Mueller, G. P., 972
- I**
- Ignatova, E., *see* Belcheva, M. M., 173
 Im, H. K., Im, W. B., Hamilton, B. J., Carter, D. B., and Vonvoigtlander, P. F. Potentiation of γ -aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the $\alpha 1\gamma 2$, $\beta 2\gamma 2$ and $\alpha 1\beta 2\gamma 2$ subtypes of cloned γ -aminobutyric acid type A receptors, 866
 Im, H. K., Im, W. B., Judge, T. M., Gammill, T. B., Hamilton, B. J., Carter, D. B., and Pregenzer, J. F. Substituted pyrazinones, a new class of allosteric modulators for γ -aminobutyric acid_A receptors, 468
 Im, H. K., *see* Dillon, G. H., 860
 Im, W. B., *see* Dillon, G. H., 860
 Im, W. B., *see* Im, H. K., 468, 866
 Inouye, N., *see* Yuasa, S., 895
 Inturrisi, C. E., *see* Zhu, Y.-S., 328
- J**
- Jackson, R. C., *see* Fry, D. W., 479
 Jansen, R. W., Schols, D., Pauwels, R., De Clercq, E., and Meijer, D. K. F. Novel, negatively charged, human serum albumins display potent and selective *in vitro* anti-human immunodeficiency virus type 1 activity, 1003
 Jeffreis, W. B., *see* Feng, F., 926
 Jensen, R. T., *see* Orbuch, M., 841
 Jin, Y., *see* Bradford, P. G., 292
 Johansen, T. E., *see* Yang, J., 1158
 Johns, D. G., Ahluwalia, G. S., Cooney, D. A., Mitsuya, H., and Driscoll, J. S. Enhanced stimulation by ribavirin of the 5'-phosphorylation

- and anti-human immunodeficiency virus activity of purine 2'- β -fluoro-2',3'-dideoxynucleosides, 519
- Johns, R. A., *see* Rengasamy, A., 124
- Johnson, G. L., *see* Russell, M., 255
- Johnson, M. R., *see* Melvin, L. S., 1008
- Johnson, R., *see* Bachur, N. R., 1064
- Jones, M. V., *see* Harrison, N. L., 628
- Joost, H. G., *see* Breiner, M., 271
- Jordan, S. J., *see* Kadiiska, M. B., 222
- Judge, T. M., *see* Dillon, G. H., 860
- Judge, T. M., *see* Im, H. K., 468
- K**
- Kadiiska, M. B., Hanna, P. M., Jordan, S. J., and Mason, R. P. Electron spin resonance evidence for free radical generation in copper-treated vitamin E- and selenium-deficient rats: *in vivo* spin-trapping investigation, 222
- Kamal, J. J., *see* Maguire, P. A., 1246
- Kapatos, G., *see* Castellano, M. A., 649
- Karlsson, A., *see* Balzarini, J., 694
- Kasai, M., *see* Siegel, D., 1128
- Kazanietz, M. G., Areces, L. B., Bahador, A., Mischak, H., Goodnight, J., Mushinski, J. F., and Blumberg, P. M. Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes, 298
- Keilbaugh, S. A., Hobbs, G. A., and Simpson, M. V. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: Prevention of 2',3'-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate, 702
- Keith, D. E., Jr., *see* Von Zastrow, M., 166
- Keith, R. A., *see* Lampe, R. A., 451
- Kemp, J. A., *see* Hadingham, K. L., 1211
- Kemp, J. A., *see* Priestley, T., 1252
- Kemp, J. A., *see* Wafford, K. A., 437
- Kenney, M. A., *see* Beaumont, K., 493
- Keren, O., *see* Baumhaker, Y., 461
- Kerker, J., *see* Michel, M. D., 1165
- Kerry, C. J., Sudan, H. L., Abutidze, K., Mellor, I. R., Barnard, E. A., and Usherwood, P. N. R. Reconstitution of glutamate receptor proteins purified from *Xenopus* central nervous system into artificial bilayers, 142
- Kim, W.-K., Hawthorn, M., and Rabin, R. A. Differential effects of chronic ethanol exposure on ATP- and bradykinin-induced increases in intracellular calcium levels in PC-12 cells, 405
- Kirkman, R. L., *see* Bennett, L. L., Jr., 1258
- Kitada, M., *see* Nakasa, H., 216
- Kiuchi, M., *see* Nakasa, H., 216
- Klatt, P., *see* Schmidt, K., 615
- Kobilka, B. K., *see* Suryanarayana, S., 111
- Koller, K. J., *see* MacArthur, L., 545
- Komiya, M., *see* Nakasa, H., 216
- Kong, H., Raynor, K., Yasuda, K., Bell, G. I., and Reisine, T. Mutation of an aspartate at residue 89 in somatostatin receptor subtype 2 prevents Na⁺ regulation of agonist binding but does not alter receptor-G protein association, 380
- Kong, H., *see* Raynor, K., 385
- Kong, H., *see* Reisine, T., 1016
- Kornreich, W. D., *see* Rogers, G. A., 633
- Koropatnick, J., and Pearson, J. Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein, 44
- Korpi, E. R., and Luddens, H. Regional γ -aminobutyric acid sensitivity of *t*-butylbicyclophosphorothionate binding depends on γ -aminobutyric acid, receptor α subunit, 87
- Kozikowski, A. P., *see* Cusack, B., 1036
- Krausa, S. W., Ghirnikar, R. B., Diamond, I., and Gordon, A. S. Inhibition of adenosine uptake by ethanol is specific for one class of nucleoside transporters, 1021
- Kucharewicz, S. A., *see* Zgombick, J. M., 575
- Kugler, J. L., *see* Harrison, N. L., 628
- Kula, N. S., *see* Booth, R. G., 1232
- Kumar, C., *see* Bergama, D. J., 277
- Kumar, C. S., Nuthulaganti, P., Pullen, M., and Nambi, P. Novel endothelin receptors in the follicular membranes of *Xenopus laevis* oocytes mediate calcium responses by signal transduction through gap junctions, 153
- Kuttesch, J. F., *see* Horton, J. K., 552
- L**
- Lagarde, M., *see* Marcoz, P., 1027
- Lahnern, K. N., *see* Granneman, J. G., 264
- Lai, H.-L., *see* Chern, Y., 950
- Lamme, E. K., *see* Goepfert, A. R., 1267
- Lampe, R. A., DeFeo, P. A., Davison, M. D., Young, J., Herman, J. L., Spreen, R. C., Horn, M. B., Mangano, T. J., and Keith, R. A. Isolation and pharmacological characterization of ω -grammatxin SIA, a novel peptide inhibitor of neuronal voltage-sensitive calcium channel responses, 451
- Lang, H. J., *see* Counillon, L., 1041
- Lavelle, F., *see* Poddevin, B., 767
- Lazo, J. S., *see* Calmels, T. P. G., 1135
- Leith, M. K., *see* Begleiter, A., 210
- Leopold, W. R., *see* Fry, D. W., 479
- Li, C., Aguayo, L., Peoples, R. W., and Weight, F. F. Ethanol inhibits a neuronal ATP-gated ion channel, 871
- Li, W. W., *see* Fanin, R., 13
- Li, Y., Llewellyn, L., and Moczydlowski, E. Biochemical and immunochemical comparison of saxiphilin and transferrin, two structurally related plasma proteins from *Rana catesbeiana*, 742
- Liang, J.-S., *see* Max, S. I., 1171
- Liang, Y., *see* Chern, Y., 950
- Liao, J.-F., and Perkins, J. P. Differential effects of antimycin A on endocytosis and exocytosis of transferrin also are observed for internalization and externalization of β -adrenergic receptors, 364
- Liedtke, R. R., *see* Boundy, V. A., 677
- Liggett, S. B., *see* Eason, M. G., 70
- Lin, C. W., *see* Frail, D. E., 1113
- Lin, C. W., *see* Wu-Wong, J. R., 285
- Lin, W.-W., and Chuang, D.-M. Endothelin- and ATP-induced inhibition of adenylyl cyclase activity in C₆ glioma cells: role of G_i and calcium, 158
- Lin, Y.-J., Greif, G. J., and Freedman, J. E. Multiple sulfonylurea-sensitive potassium channels: A novel subtype modulated by dopamine, 907
- Linden, J., Taylor, H. E., Robeva, A. S., Tucker, A. L., Stähle, J. H., Rivkees, S. A., Fink, J. S., and Reppert, S. M. Molecular cloning and functional expression of a sheep A₃ adenosine receptor with widespread tissue distribution, 524
- Lindstrom, J., *see* Anand, R., 1046
- Linville, D., *see* Hamel, E., 242
- Little, J., *see* Aharony, D., 356
- Liu, C., *see* Wilcox, R. A., 810
- Liu, E. C. K., *see* Webb, M. L., 959
- Liu, F., *see* Feng, F., 926
- Liu, J., *see* Chen, Y., 8
- Liu, L.-X., *see* Castellano, M. A., 649
- Liu-Chen, L.-Y., Chen, C., and Phillips, C. A. β -[³H]Funtretamine-labeled μ -opioid receptors: Species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides, 749
- Llewellyn, L., *see* Li, Y., 742
- Loew, G. H., *see* Davies, M. F., 876
- Loew, G. H., *see* Maguire, P. A., 1246
- Logsdon, C. D., *see* Yang, J., 1158
- Lorenzen, A., Fuss, M., Vogt, H., and Schwabe, U. Measurement of

- guanine nucleotide-binding protein activation by A₁ adenosine receptor agonists in bovine brain membranes: stimulation of guanosine-5'-O-(3-[³⁵S]thio)triphosphate binding, 115
- Loyer, P., *see* Abdel-Razzak, Z., 707
- Lucero, L., *see* Lukas, R. J., 680
- Lüddens, H., *see* Korpi, E. R., 87
- Luetje, C. W., Piattoni, M., and Patrick, J. Mapping of ligand binding sites of neuronal nicotinic acetylcholine receptors using chimeric α subunits, 657
- Lukas, R. J., Audhya, T., Goldstein, G., and Lucero, L. Interactions of the thymic polypeptide hormone thymopoietin with neuronal nicotinic α -bungarotoxin binding sites and with muscle-type, but not ganglia-type, nicotinic acetylcholine receptor ligand-gated ion channels, 680
- Lynch, J., *see* Webb, M. L., 959
- M**
- Ma, H., *see* Yu, H. J., 689
- MacArthur, L., Koller, K. J., and Eiden, L. E. Enkephalin gene transcription in bovine chromaffin cells is regulated by calcium and protein kinase A signal transduction pathways: identification of DNase I-hypersensitive sites, 545
- MacDonald, P., *see* Strömstedt, M., 1077
- MacDonald, R. L., *see* Angelotti, T. P., 1202
- MacKenzie, R. G., *see* Frail, D. E., 1113
- Mackie, K., Devane, W. A., and Hille, B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells, 498
- Mackler, S. A., and Eberwine, J. H. Diversity of glutamate receptor subunit mRNA expression within live hippocampal CA1 neurons, 308
- Magnuson, S. R., *see* Wu-Wong, J. R., 285
- Maguire, P. A., Perez, J. J., Tsai, N. F., Rodriguez, L., Beatty, M. F., Villar, H. O., Kamal, J. J., Upton, C., Casy, A. F., and Loew, G. H. Molecular mechanism of δ -selectivity of indole analogs in nonpeptide opioids, 1246
- Maguire, P. A., *see* Davies, M. F., 876
- Mahan, L. C., *see* Raynor, K., 385
- Maigret, B., *see* Blin, N., 1094
- Mailman, R. B., *see* Booth, R. G., 1232
- Mains, R. E., *see* Mueller, G. P., 972
- Mak, J. C. W., *see* Miyayasu, K., 539
- Malapetaa, A., *see* Nē, A. J., 204
- Malkas, L., *see* Bachur, N. R., 1064
- Manelli, A. M., *see* Frail, D. E., 1113
- Mangano, T. J., *see* Lampe, R. A., 451
- Mantey, S. A., *see* Orbuch, M., 841
- Mao, X., *see* Wadler, S., 1070
- Marcoz, P., Prigent, A. F., Lagarde, M., and Némoy, G. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents, 1027
- Maren, T. H., Wynns, G. C., and Wistrand, P. J. Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme, 901
- Marin, P., Stella, N., Cordier, J., Glowinski, J., and Prémont, J. Role of arachidonic acid and glutamate in the formation of inositol phosphates induced by noradrenalin in striatal astrocytes, 1176
- Mason, R. P., *see* Kadiiska, M. B., 222
- Max, S. I., Liang, J.-S., and Potter, L. T. Stable allosteric binding of m1-toxin to m1 muscarinic receptors, 1171
- Mayer, B., *see* Schmidt, K., 615
- Mayer, M. L., *see* Wong, L. A., 504
- McCarthy, K. D., *see* Shao, Y., 247
- McGuire, R., *see* Calmels, T. P. G., 1135
- McHale, R. J., *see* Belcheva, M. M., 173
- McIntyre, P., Phillips, E., Skidmore, E., Brown, M., and Webb, M. Cloned murine bradykinin receptor exhibits a mixed B₁ and B₂ pharmacological selectivity, 346
- McNutt, R. W., *see* Childers, S. R., 827
- McPheat, W. L., *see* Aharony, D., 356
- Meijer, D. K. F., *see* Jansen, R. W., 1003
- Mellor, I. R., *see* Kerry, C. J., 142
- Melvin, L. S., Milne, G. M., Johnson, M. R., Subramaniam, B., Wilken, G. H., and Howlett, A. C. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: Studies of bicyclic cannabinoid analogs, 1008
- Mesange, F., *see* Chailleux, C., 324
- Mestek, A., *see* Chen, Y., 8
- Michel, M. C., Kerker, J., Brancheck, T. A., and Forray, C. Selective irreversible binding of chloroethylclonidine at α_1 - and α_2 -adrenoceptor subtypes, 1165
- Miksaicek, R. J. Commonly occurring plant flavonoids have estrogenic activity, 37
- Miller, J. M., *see* Gioannini, T. L., 796
- Miller, K. W., *see* Wood, S. C., 1219
- Milligan, G., *see* Georgoussi, Z., 62
- Milne, G. M., *see* Melvin, L. S., 1008
- Minneman, K. P., *see* Esbenshade, T. A., 76
- Minneman, K. P., *see* Zhong, H., 1085
- Mintz, I. M., *see* Adams, M. E., 681
- Mischak, H., *see* Kazanietz, M. G., 298
- Mistry, J. S., *see* Calmels, T. P. G., 1135
- Mitsuya, H., *see* Johns, D. G., 519
- Miyayasu, K., Mak, J. C. W., Nishikawa, M., and Barnes, P. J. Characterization of guinea pig pulmonary neurokinin type 1 receptors using a novel antagonist ligand, [³H]FK888, 539
- Moczydlowski, E., *see* Li, Y., 742
- Mode, A., *see* Westin, S., 997
- Mody, H. I., *see* Dilger, J. P., 1056
- Moebius, F. F., Burrows, G. G., Hanner, M., Schmid, E., Striessnig, J., and Glossmann, H. Identification of a 27-kDa high affinity phenylalkylamine-binding polypeptide as the σ_1 binding site by photoaffinity labeling and ligand-directed antibodies, 966
- Mok, W. M., *see* Wang, G. K., 667
- Molinoff, P. B., *see* Boundy, V. A., 677
- Molinoff, P. B., *see* Filtz, T. M., 371
- Monshizadegan, H., *see* Webb, M. L., 959
- Monsma, F. J., Jr., *see* Castellano, M. A., 649
- Montgomery, J. A., *see* Bennett, L. L., Jr., 1258
- Moran, N., *see* Funk, C. D., 934
- Moreau, J.-P., *see* Orbuch, M., 841
- Morin, D., *see* Plopper, C. G., 51
- Mrozinski, J. E., Jr., *see* Orbuch, M., 841
- Mueller, G. P., Husten, E. J., Mains, R. E., and Eipper, B. A. Peptide α -amidation and peptidylglycine α -hydroxylating monooxygenase: Control by disulfiram, 972
- Muhoherac, B. B., *see* Carfagna, M. A., 129
- Muller, J., *see* Schouten, D., 486
- Müller-Weiland, D., *see* Breiner, M., 271
- Munshi, R., DeBernardi, M. A., and Brooker, G. P_{2U}-purinergic receptors on C6-2B rat glioma cells: Modulation of cytosolic Ca²⁺ and cAMP levels by protein kinase C, 1185
- Murphy, T. J., Nakamura, Y., Takeuchi, K., and Alexander, R. W. A cloned angiotensin receptor isoform from the turkey adrenal gland is pharmacologically distinct from mammalian angiotensin receptors, 1
- Murphy, T. J., *see* Esbenshade, T. A., 76
- Murray, M., *see* Westin, S., 997
- Mushinski, J. F., *see* Kazanietz, M. G., 298
- Myers, A. M., *see* Booth, R. G., 1232
- N**
- Nahorski, S. R., *see* Wilcox, R. A., 810
- Nakamura, Y., *see* Murphy, T. J., 1

- Nakasa, H., Komiya, M., Ohmori, S., Rikihisa, T., Kiuchi, M., and Kitada, M. Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide, 216
- Nambi, P., *see* Bergsma, D. J., 277
- Nambi, P., *see* Kumar, C. S., 153
- Nash, S. R., Godinot, N., and Caron, M. G. Cloning and characterization of the opossum kidney cell D1 dopamine receptor: Expression of identical D1A and D1B dopamine receptor mRNAs in opossum kidney and brain, 918
- Nathanson, N. M., *see* Blake, A. D., 716
- Némoz, G., *see* Marcoz, P., 1027
- Nicoletti, F., *see* Aronica, E., 981
- Nishikawa, M., *see* Miyayasu, K., 539
- Noë, A. J., Malapetsa, A., and Panasci, L. C. Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system, 204
- Nuthulaganti, P., *see* Kumar, C. S., 153
- Nuthulaganti, P. R., *see* Bergsma, D. J., 277
- Nuttie, L. C., El-Moatassim, C., and DUBYAK, G. R. Expression of the pore-forming P₂₂ purinoreceptor in *Xenopus* oocytes injected with poly(A)⁺ RNA from murine macrophages, 93

O

- O'Carroll, A.-M., *see* Raynor, K., 385
- Ohmori, S., *see* Nakasa, H., 216
- Omicinski, C. J., *see* Schilter, B., 990
- Ong, M. S., *see* Probst, M. R., 511
- Oppenorth, T. J., *see* Wu-Wong, J. R., 422
- Orbuch, M., Taylor, J. E., Coy, D. H., Mrozinski, J. E., Jr., Mantey, S. A., Battey, J. F., Moreau, J.-P., and Jensen, R. T. Discovery of a novel class of neuropeptide B receptor antagonists, substituted somatostatin analogues, 841
- Osman, R., *see* Smolyar, A., 882

P

- Palmer, K. J., *see* Hadingham, K. L., 1211
- Panasci, L. C., *see* Nö, A. J., 204
- Pang, Y.-P., *see* Cusack, B., 1036
- Parker, W. B., *see* Bennett, L. L., Jr., 1258
- Paroli, L., *see* Canga, L., 1142
- Patrick, J., *see* Luetje, C. W., 657
- Patrick, J., *see* Quik, M., 678
- Pauwels, R., *see* Jansen, R. W., 1003
- Pearson, J., *see* Koropatnick, J., 44
- Pecher, C., *see* Bascands, J.-L., 818
- Peng, X., *see* Anand, R., 1046
- Peoples, R. W., *see* Li, C., 871
- Pepperl, D. J., and Regan, J. W. Selective coupling of α_2 -adrenergic receptor subtypes to cyclic AMP-dependent reporter gene expression in transiently transfected JEG-3 cells, 802
- Perez, D. M., DeYoung, M. B., and Graham, R. M. Coupling of expressed α_{1B} - and α_{1D} -adrenergic receptors to multiple signaling pathways is both G protein and cell type specific, 784
- Perez, J. J., *see* Maguire, P. A., 1246
- Perkins, J. P., *see* Liao, J.-F., 364
- Persons, S. M., *see* Rogers, G. A., 633
- Pettit, G. R., *see* Bai, R., 757
- Phillips, C. A., *see* Liu-Chen, L.-Y., 749
- Phillips, E., *see* McIntyre, P., 346
- Philpot, R. M., *see* Plopper, C. G., 51
- Piattoni, M., *see* Luetje, C. W., 657
- Pieters, M. N., *see* Schouten, D., 486
- Piqué, J. M., *see* Goeptar, A. R., 1267
- Plassat, J.-L., Amlaiky, N., and Hen, R. Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase, 229
- Plopper, C. G., Weir, A. J., Morin, D., Chang, A., Philpot, R. M., and

- Buckpitt, A. R. Postnatal changes in the expression and distribution of pulmonary cytochrome P450 monooxygenases during Clara cell differentiation in rabbits, 51
- Poddevin, B., Riou, J.-F., Lavelle, F., and Pommier, Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials, 767
- Pommier, Y., *see* Poddevin, B., 767
- Potter, B. V. L., *see* Wilcox, R. A., 810
- Potter, L. T., *see* Max, S. I., 1171
- Pouyssegur, J., *see* Counillon, L., 1041
- Powell, S., *see* Aharony, D., 356
- Prats, A.-C., *see* Chailleux, C., 324
- Pregenzer, J. F., *see* Im, H. K., 468
- Prémont, J., *see* Marin, P., 1176
- Priestley, T., and Kemp, J. A. Agonist response kinetics of *N*-methyl-D-aspartate receptors in neurons cultured from rat cerebral cortex and cerebellum: Evidence for receptor heterogeneity, 1252
- Prigent, A. F., *see* Marcoz, P., 1027
- Pritchett, D. B., *see* Harrison, N. L., 628
- Probst, M. R., Reisz-Porszasz, S., Agbunag, R. V., Ong, M. S., and Hankinson, O. Role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon (dioxin) receptor action, 511
- Proll, M. A., Clark, R. B., and Butcher, R. W. β_2 -Adrenergic receptor mutants reveal structural requirements for the desensitization observed with long term epinephrine treatment, 569
- Pullen, M., *see* Kumar, C. S., 153

Q

- Querimit, L. A., *see* Charness, M. E., 1119
- Quik, M., Afar, R., Geertsens, S., Audhya, T., Goldstein, G., and Trifaro, J. M. Thymopoietin, a thymic polypeptide regulates nicotinic α -bungarotoxin sites in chromaffin cells in culture, 680
- Quik, M., Cook, R. G., Revah, F., Changeux, J.-P., and Patrick, J. Commentary: Presence of α -cobratoxin and phospholipase A₂ activity in thymopoietin preparations, 678
- Quik, M., El-Bizri, H., Audhya, T., and Goldstein, G. Thymopoietin, a potent antagonist at nicotinic receptors in C2 muscle cell cultures, 680

R

- Rabin, R. A., *see* Kim, W.-K., 405
- Raess, B. U. Irreversible modification of red cell Ca²⁺ transport by phenylglyoxal, 399
- Ragan, C. I., *see* Hadingham, K. L., 1211
- Rajendra, S., *see* Vandenberg, R. J., 198
- Rampe, D., Wible, B., Brown, A. M., and Dage, R. C. Effects of terfenadine and its metabolites on a delayed rectifier K⁺ channel cloned from human heart, 1240
- Rampe, D., Wible, B., Fedida, D., Dage, R. C., and Brown, A. M. Verapamil blocks a rapidly activating delayed rectifier K⁺ channel cloned from human heart, 642
- Raynor, K., O'Carroll, A.-M., Kong, H., Yasuda, K., Mahan, L. C., Bell, G. I., and Reisine, T. Characterization of cloned somatostatin receptors SSTR4 and SSTR5, 385
- Raynor, K., *see* Kong, H., 380
- Raynor, K., *see* Reisine, T., 1016
- Redman, R. S., and Silinsky, E. M. A selective adenosine antagonist (8-cyclopentyl-1,3-dipropylxanthine) eliminates both neuromuscular depression and the action of exogenous adenosine by an effect on A₁ receptors, 835
- Regan, J. W., *see* Pepperl, D. J., 802
- Reily, M. D., *see* Adams, M. E., 681
- Reisine, T., Kong, H., Raynor, K., Yano, H., Takeda, J., Yasuda, K., and Bell, G. I. Splice variant of the somatostatin receptor 2 subtype, somatostatin receptor 2B, couples to adenylyl cyclase, 1016
- Reisine, T., *see* Kong, H., 380

- Reisine, T., *see* Raynor, K., 385
 Reisz-Porszasz, S., *see* Probst, M. R., 511
 Rengasamy, A., and Johns, R. A. Regulation of nitric oxide synthase by nitric oxide, 124
 Renton, K. W., *see* Armstrong, S. G., 677
 Reppert, S. M., *see* Linden, J., 524
 Revah, F., *see* Quik, M., 678
 Rhee, J. P., *see* Wolfe, A. D., 1152
 Richelson, E., *see* Cusack, B., 1036
 Rifkind, A. B., *see* Canga, L., 1142
 Rikihisa, T., *see* Nakasa, H., 216
 Rink, T. J., *see* Beaumont, K., 493
 Riou, J.-F., *see* Poddevin, B., 767
 Rivkees, S. A., *see* Linden, J., 524
 Robbins, P. D., *see* Calmels, T. P. G., 1135
 Robeva, A. S., *see* Linden, J., 524
 Rodriguez, L., *see* Maguire, P. A., 1246
 Rogawski, M. A., *see* Werkman, T. R., 430
 Rogers, G. A., Kornreich, W. D., Hand, K., and Persons, S. M. Kinetic and equilibrium characterization of vesamicol receptor-ligand complexes with picomolar dissociation constants, 633
 Rogowski, R. S., *see* Werkman, T. R., 430
 Romero-Avila, M. T., *see* Garcia-Sáinz, J. A., 589
 Rose, L. M., *see* Bennett, L. L., Jr., 1258
 Rose, P. M., *see* Webb, M. L., 959
 Ross, D., *see* Siegel, D., 1128
 Rudnick, G., *see* Schuldiner, S., 1227
 Ruest, L., *see* Humerickhouse, R. A., 412
 Russell, M., and Johnson, G. L. G protein amino-terminal α_{12}/α_{13} chimeras reveal amino acids important in regulating α activity, 255
- S**
- Sadakata, Y., *see* Yuasa, S., 895
 Saeed, M., *see* Wolfe, A. D., 1152
 Sanders-Buch, E., *see* Barker, E. L., 725
 Sarne, Y., *see* Baumhaker, Y., 461
 Sattelle, D. B., *see* Blake, A. D., 716
 Saunders, P. A., *see* Fukamauchi, F., 940
 Scaife, K., *see* Bergama, D. J., 277
 Schilter, B., and Omiecinski, C. J. Regional distribution and expression modulation of cytochrome P-450 and epoxide hydrolase mRNAs in the rat brain, 990
 Schmid, E., *see* Moebius, F. F., 966
 Schmidt, J. V., *see* Dolwick, K. M., 911
 Schmidt, K., Klatt, P., and Mayer, B. Characterization of endothelial amino acid transport systems involved in the actions of nitric oxide synthase inhibitors, 615
 Schofield, P. R., *see* Vandenberg, R. J., 198
 Schols, D., *see* Jansen, R. W., 1003
 Scholz, W., *see* Counillon, L., 1041
 Schouten, D., van der Kooij, M., Muller, J., Pieters, M. N., Bijsterbosch, M. K., and van Berkel, T. J. C. Development of lipoprotein-like lipid particles for drug targeting: Neo-high density lipoproteins, 486
 Schuldiner, S., Steiner-Mordoch, S., Yelin, R., Wall, S. C., and Rudnick, G. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters, 1227
 Schwabe, U., *see* Lorenzen, A., 115
 Schwartz, E. L., *see* Wadler, S., 1070
 Schweitzer, B. I., *see* Fanin, R., 13
 Scofield, M., *see* Feng, F., 926
 Scutari, E., *see* Zorzato, F., 1192
 Secrist, J. A., III, *see* Bennett, L. L., Jr., 1258
 Seidenberg, M., *see* Ellis, J., 583
 Sekiya, K., *see* Yuasa, S., 895
 Selley, D. E., Breivogel, C. S., and Childers, S. R. Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: Increase in opioid agonist efficacy by decreased inactivation of G proteins, 731
 Selley, D. E., *see* Childers, S. R., 827
 Shannon, W. M., *see* Bennett, L. L., Jr., 1258
 Shao, Y., and McCarthy, K. D. Quantitative relationship between α_1 -adrenergic receptor density and the receptor-mediated calcium response in individual astroglial cells, 247
 Shaw, P. M., Adesnik, M., Weiss, M. C., and Corcos, L. The phenobarbital-induced transcriptional activation of cytochrome P-450 genes is blocked by the glucocorticoid-progesterone antagonist RU486, 775
 Shealy, Y. F., *see* Bennett, L. L., Jr., 1258
 Sibley, D. R., *see* Castellano, M. A., 649
 Siegel, D., Beall, H., Kasai, M., Arai, H., Gibson, N. W., and Ross, D. pH-dependent inactivation of DT-diaphorase by mitomycin C and porfomycin, 1128
 Sikela, J. M., *see* Hadingham, K. L., 1211
 Silinsky, E. M., *see* Redman, R. S., 835
 Silver, R. B., *see* Canga, L., 1142
 Simasko, S. M., and Yan, S. 3-Isobutyl-1-methylxanthine inhibits sustained calcium current independently of cyclic AMP in neuronal and endocrine cells, 622
 Simon, E. J., *see* Gioannini, T. L., 796
 Simon, R., *see* Wang, G. K., 667
 Simpson, M. V., *see* Keilbaugh, S. A., 702
 Skeen, G. A., Twyman, R. E., and White, H. S. The dihydropyridine nitrendipine modulates N-methyl-D-aspartate receptor channel function in mammalian neurons, 443
 Skidmore, E., *see* McIntyre, P., 346
 Smit, M. J., *see* Anderson, R., 605
 Smolyar, A., and Osman, R. Role of threonine 342 in helix 7 of the 5-hydroxytryptamine type 1D receptor in ligand binding: An indirect mechanism for receptor selectivity, 882
 Spreen, R. C., *see* Lampe, R. A., 451
 Srinivas, R. V., *see* Gong, Y.-F., 30
 Steffey, M. E., *see* Frail, D. E., 1113
 Stehle, J. H., *see* Linden, J., 524
 Steiner-Mordoch, S., *see* Schuldiner, S., 1227
 Stella, N., *see* Marin, P., 1176
 Sterling, K., Weaver, J., Ho, K. L., Xu, L. C., and Breanick, E. Rat CYP1A1 negative regulatory element: Biological activity and interaction with a protein from liver and hepatoma cells, 560
 Streicher, R., *see* Breiner, M., 271
 Striessnig, J., *see* Moebius, F. F., 966
 Strömstedt, M., Warner, M., Banner, C. D., MacDonald, P. C., and Gustafsson, J.-A. Role of brain cytochrome P450 in regulation of the level of anesthetic steroids in the brain, 1077
 Strosberg, A. D., *see* Blin, N., 1094
 Su, Y.-M., *see* Cheng, H.-F., 533
 Subramaniam, B., *see* Melvin, L. S., 1008
 Sudan, H. L., *see* Kerry, C. J., 142
 Suryanarayana, S., and Kobilka, B. K. Amino acid substitutions at position 312 in the seventh hydrophobic segment of the β_2 -adrenergic receptor modify ligand-binding specificity, 111
 Sutko, J. L., *see* Humerickhouse, R. A., 412
 Swanson, H. I., *see* Dolwick, K. M., 911
 Sweitzer, N. M., *see* de S. Otero, A., 595
- T**
- Tagliatela, M., Drewe, J. A., and Brown, A. M. Barium blockade of a clonal potassium channel and its regulation by a critical pore residue, 180
 Takashima, H., *see* Yuasa, S., 895
 Takeda, J., *see* Reisine, T., 1016
 Takeuchi, K., *see* Murphy, T. J., 1
 Tang, L.-H., and Aizenman, E. Long-lasting modification of the N-methyl-D-aspartate receptor channel by a voltage-dependent sulfhydryl redox process, 473

- Taylor, H. E., *see* Linden, J., 524
Taylor, J. E., *see* Orbach, M., 841
Taylor, L. P., *see* Gioannini, T. L., 796
Tegazzin, V., *see* Zorzato, F., 1192
Te Koppele, J. M., *see* Goepfert, A. R., 1267
Thanabal, V., *see* Adams, M. E., 681
Thimmaiah, K. N., *see* Horton, J. K., 552
Thomas, E. A., Baker, S. A., and Ehlert, F. J. Functional role for the M₂ muscarinic receptor in smooth muscle of the guinea pig ileum, 102
Timmerman, H., *see* Eriks, J. C., 886
Ting, V., *see* Hamel, E., 242
Treves, S., *see* Zorzato, F., 1192
Trifaro, J. M., *see* Quik, M., 680
Tsai, N. F., *see* Maguire, P. A., 1246
Tucker, A. L., *see* Linden, J., 524
Turlin, B., *see* Abdel-Razzak, Z., 707
Twyman, R. E., *see* Skeen, G. A., 443

U

- Ubasawa, M., *see* Yuasa, S., 895
Uhler, M. D., *see* Angelotti, T. P., 1202
Upton, C., *see* Maguire, P. A., 1246
Usherwood, P. N. R., *see* Kerry, C. J., 142

V

- van Berkel, T. J. C., *see* Schouten, D., 486
Vandenberg, R. J., Rajendra, S., French, C. R., Barry, P. H., and Schofield, P. R. The extracellular disulfide loop motif of the inhibitory glycine receptor does not form the agonist binding site, 198
Van der Goot, H., *see* Eriks, J. C., 886
van der Kooij, M., *see* Schouten, D., 486
Van Rensburg, C. E. J., *see* Anderson, R., 605
Vermeulen, N. P. E., *see* Goepfert, A. R., 1267
Villar, H. O., *see* Maguire, P. A., 1246
Villemure, J.-G., *see* Hamel, E., 242
Vogt, H., *see* Lorenzen, A., 115
Volkenandt, M., *see* Fanin, R., 13
Vonvoigtlander, P. F., *see* Im, H. K., 866
Von Zastrow, M., Keith, D. E., Jr., and Evans, C. J. Agonist-induced state of the δ -opioid receptor that discriminates between opioid peptides and opiate alkaloids, 166

W

- Wachtel, R. E. Physostigmine block of ion channels activated by acetylcholine in BC3H1 cells, 1051
Wadler, S., Mao, X., Bajaj, R., Hallam, S., and Schwartz, E. L. *N*-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon- α -2a against human colon cancer cell lines, 1070
Wafford, K. A., Bain, C. J., Whiting, P. J., and Kemp, J. A. Functional comparison of the role of γ subunits in recombinant human γ -aminobutyric acid/benzodiazepine receptors, 437
Wafford, K. A., *see* Hadingham, K. L., 1211
Wall, S. C., *see* Schuldiner, S., 1227
Waltham, M., *see* Fanin, R., 13
Wang, G. K., Simon, R., Bell, D., Mok, W. M., and Wang, S.-Y. Structural determinants of quaternary ammonium blockers for batrachotoxin-modified Na⁺ channels, 667
Wang, S.-Y., *see* Wang, G. K., 667
Warner, M., *see* Strömstedt, M., 1077
Watkins, S. C., *see* Calmels, T. P. G., 1135
Weaver, J., *see* Sterling, K., 560
Webb, M., *see* McIntyre, P., 346
Webb, M. L., Liu, E. C. K., Monshizadegan, H., Chao, C.-C., Lynch, J., Fisher, S. M., and Rose, P. M. Expression of endothelin receptor subtypes in rabbit saphenous vein, 959
Weight, F. F., *see* Li, C., 871

- Weiland, M., *see* Breiner, M., 271
Weinshank, R. L., *see* Zgombick, J. M., 575
Weir, A. J., *see* Plopper, C. G., 51
Weiss, M. C., *see* Shaw, P. M., 775
Werkman, T. R., Gustafson, T. A., Rogowski, R. S., Blaustein, M. P., and Rogawski, M. A. Tityustoxin-K α , a structurally novel and highly potent K⁺ channel peptide toxin, interacts with the α -dendrotoxin binding site on the cloned Kv1.2 K⁺ channel, 430
Westin, S., Mode, A., Murray, M., Chen, R., and Gustafsson, J.-A. Growth hormone and vitamin A induce P450C7 mRNA expression in primary rat hepatocytes, 997
White, H. S., *see* Skeen, G. A., 443
White, M. M., *see* Filatov, G. N., 237
Whiting, P. J., *see* Hadingham, K. L., 1211
Whiting, P. J., *see* Wafford, K. A., 437
Wible, B., *see* Rampe, D., 642, 1240
Wilcox, A. S., *see* Hadingham, K. L., 1211
Wilcox, R. A., Challias, R. A. J., Liu, C., Potter, B. V. L., and Nahoraki, S. R. Inositol-1,3,4,5-tetrakisphosphate induces calcium mobilization via the inositol-1,4,5-trisphosphate receptor in SH-SY5Y neuroblastoma cells, 810
Wilken, G. H., *see* Melvin, L. S., 1008
Williams, J. A., *see* Yang, J., 1158
Williams, K. Ifenprodil discriminates subtypes of the *N*-methyl-D-aspartate receptor: Selectivity and mechanisms at recombinant heteromeric receptors, 851
Wilson, A. W., *see* Hadingham, K. L., 1211
Wingrove, P. B., *see* Hadingham, K. L., 1211
Wistrand, P. J., *see* Maren, T. H., 901
Witte, D. G., *see* Frail, D. E., 1113
Witte, D. G., *see* Wu-Wong, J. R., 285
Wolfe, A. D., Chiang, P. K., Doctor, B. P., Fryar, N., Rhee, J. P., and Saeed, M. Monoclonal antibody AE-2 modulates carbamate and organophosphate inhibition of fetal bovine serum acetylcholinesterase, 1152
Wolff, D. W., *see* Feng, F., 926
Wong, L. A., and Mayer, M. L. Differential modulation by cyclothiazide and concanavalin A of desensitization at native α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid- and kainate-preferring glutamate receptors, 504
Wood, S. C., Hill, W. A., and Miller, K. W. Cycloalkane methanols discriminate between volume- and length-dependent loss of activity of alkanols at the *Torpedo* nicotinic acetylcholine receptor, 1219
Wu, X.-P., and Dolnick, B. J. 5-Fluorouracil alters dihydrofolate reductase pre-mRNA splicing as determined by quantitative polymerase chain reaction, 22
Wu-Wong, J. R., Chiou, W., Magnuson, S. R., Witte, D. G., and Lin, C. W. Identification and characterization of type A endothelin receptors in MMQ cells, 285
Wu-Wong, J. R., Chiou, W. J., and Ogenorth, T. J. Phosphoramidon modulates the number of endothelin receptors in cultured Swiss 3T3 fibroblasts, 422
Wynns, G. C., *see* Maren, T. H., 901
Wyrick, S. D., *see* Booth, R. G., 1232

X

- Xu, L. C., *see* Sterling, K., 560

Y

- Yan, S., *see* Simasko, S. M., 622
Yang, J., Logsdon, C. D., Johansen, T. E., and Williams, J. A. Human m3 muscarinic acetylcholine receptor carboxyl-terminal threonine residues are required for agonist-induced receptor down-regulation, 1158
Yano, H., *see* Reisine, T., 1016
Yao, Y. H., *see* Gioannini, T. L., 796
Yasuda, K., *see* Kong, H., 380
Yasuda, K., *see* Raynor, K., 385

- Yasuda, K., *see* Reisine, T., 1016
 Yeh, J.-R., *see* Cheng, H.-F., 533
 Yelin, R., *see* Schuldiner, S., 1227
 Young, A. A., *see* Beaumont, K., 493
 Young, J., *see* Lampe, R. A., 451
 Yu, F., *see* Bachur, N. R., 1064
 Yu, H. J., Ma, H., and Green, R. D. Calcium entry via L-type calcium channels acts as a negative regulator of adenylyl cyclase activity and cyclic AMP levels in cardiac myocytes, 689
 Yu, L., *see* Chen, Y., 8
 Yuasa, S., Sadakata, Y., Takashima, H., Sekiya, K., Inouye, N., Ubasawa, M., and Baba, M. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442, 895

Z

- Zaidi, J., *see* Cusack, B., 1036
 Zgombick, J. M., Borden, L. A., Cochran, T. L., Kucharewicz, S. A.,

Weinshank, R. L., and Branchek, T. A. Dual coupling of the cloned human 5-hydroxytryptamine_{1D}[cf10] α [cf1] and 5-hydroxytryptamine_{1D}[cf10] β [cf1] receptors stably expressed in murine fibroblasts: Inhibition of adenylyl cyclase and elevation of intracellular calcium concentrations via pertussis toxin-sensitive G protein(s), 575

Zhong, H., and Minneman, K. P. Close reciprocal regulation of β_1 - and β_2 -adrenergic receptors by dexamethasone in C₆ glioma cells: Effects on catecholamine responsiveness, 1085

Zhu, Y.-S., Brodsky, M., Franklin, S. O., Huang, T., and Inturrisi, C. E. Metrazole induces the sequential activation of c-fos, proenkephalin, and tyrosine hydroxylase gene expression in the rat adrenal: Modulation by glucocorticoid and adrenocorticotrophic hormone, 328

Zorzato, F., Scutari, E., Tegazzin, V., Clementi, E., and Treves, S. Chlorocresol: An activator of ryanodine receptor-mediated Ca²⁺ release, 1192



**Statement of Ownership,
Management and
Circulation**
(Required by 39 U.S.C. 3685)

1A. Title of Publication MOLECULAR PHARMACOLOGY		1B. PUBLICATION NO. 0 0 2 1 6 8 9 5 X		2. Date of Filing 10-1-93	
3. Frequency of Issue Monthly		2A. No. of Issues Published Annually 12		2B. Annual Subscription Price \$105.00	
4. Complete Mailing Address of Known Office of Publication (Street, City, County, State and ZIP+4 Code) (Do not print)					
428 East Preston Street, Baltimore, MD 21202-3993					
5. Complete Mailing Address of the Headquarters or General Business Office of the Publisher (Do not print)					
428 East Preston Street, Baltimore, MD 21202-3993					
6. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do not print MUST NOT be blank)					
Publisher (Name and Complete Mailing Address) Williams & Wilkins, 428 East Preston Street, Baltimore, MD 21202-3993					
Editor (Name and Complete Mailing Address) Dr. T. Kendall Harden, CB #7368, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7368					
Managing Editor (Name and Complete Mailing Address)					
7. Owner (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.) (Do not print)					
Full Name AMERICAN SOCIETY FOR PHARMACOLOGY and Experimental Therapeutics		Complete Mailing Address c/o Kay Crockett Executive Director 9650 Rockville Pike Bethesda, MD 20814			
8. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages or Other Securities. If none, so state.					
Full Name NONE		Complete Mailing Address			
9. For Completion by Nonprofit Organizations Authorized to Mail at Special Rates (GSM Section 401 (2) only) The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Check one) ☐ Has Not Changed During Preceding 12 Months ☐ Has Changed During Preceding 12 Months (If changed, publisher must submit explanation of change with this statement.)					
10. Extent and Nature of Circulation (Give estimates on reverse side)		Average No. Copies Each Issue During Preceding 12 Months		Actual No. Copies of Single Issue Published Nearest to Filing Date	
A. Total No. Copies (Net Press Run)		2232		2150	
B. Paid and/or Requested Circulation 1. Sales through dealers and carter/s (Include subscription sales)		191		189	
2. Mail Subscriptions (Paid and/or requested)		1420		1383	
C. Total Paid and/or Requested Circulation (Sum of B1 and B2)		1611		1572	
D. Free Distribution by Mail, Carrier or Other Means Samples, Complimentary, and Other Free Copies		87		98	
E. Total Distribution (Sum of C and D)		1698		1670	
F. Copies Not Distributed 1. Office use, left over, unsolicited, spoiled after printing		534		480	
2. Return from News Agents		NONE		NONE	
G. TOTAL (Sum of E, F1 and F2—should equal net press run shown in 10)		2232		2150	
11. I certify that the statements made by me above are correct and complete		Signature and Title of Editor, Publisher, Business Manager, or Owner <i>Alma J. Wilkins</i> PUBLISHER			

**Copyright © 1993 by the American Society for
Pharmacology and Experimental Therapeutics**

Leading Pharmacology Journals

Publications of the American Society for Pharmacology and Experimental Therapeutics, Inc.

The Journal of Pharmacology and Experimental Therapeutics

Editor: John A. Harvey, Ph.D.

JPET is respected the world over as one of the leading research journals in the field of pharmacology. You'll find broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology. *Monthly*.

Drug Metabolism and Disposition: the biological fate of chemicals

Editor: Vincent G. Zannoni, Ph.D.

Drug Metabolism and Disposition publishes in vitro and in vivo experimental results that bring you significant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants and preservatives. The areas covered are: pharmacokinetics, pharmacodynamics and mechanisms, genetic, nutritional, or hormonal factors affecting the biological fate of chemicals, toxicological consequences of xenobiotic metabolism. *Bimonthly*.

Pharmacological Reviews


Editor: Robert E. Stitzel, Ph.D.

Pharmacological Reviews is a showcase for important review articles in your field, featuring longer papers on topics of high current interest. The areas covered in review papers have included biochemical and cellular pharmacology, drug metabolism and disposition, renal pharmacology, neuropharmacology, behavioral pharmacology, clinical pharmacology, and toxicology. No library serving the pharmacologic community should be without a subscription. *Quarterly*.

Molecular Pharmacology

Editor: T. Kendall Harden, Ph.D.

The papers published in **Molecular Pharmacology** are on the cutting edge of research on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology are juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including such areas as molecular mechanisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anticancer drug action. *Monthly*



MEMBERS:

SAVE 10% when ordering two
SAVE 15% when ordering three
SAVE 20% when ordering four



Please enter my subscription to the following:

The Journal of Pharmacology and Experimental Therapeutics (*monthly*)

☐ Individual \$190/year ☐ Institutional \$340/year (Add \$65/year for subscriptions outside the U.S.; in Canada, also add 7% GST.)

☐ New Subscription ☐ Renewal

Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

Drug Metabolism and Disposition (*bimonthly*)

☐ Individual \$85/year ☐ Institutional \$140/year (Add \$20/year for subscriptions outside the U.S.; in Canada, also add 7% GST.)

☐ New Subscription ☐ Renewal

Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

Molecular Pharmacology (*monthly*)

☐ Individual \$105/year ☐ Institutional \$230/year (Add \$30/year for subscriptions outside the U.S.; in Canada, also add 7% GST.)

☐ New Subscription ☐ Renewal

Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

Pharmacological Reviews (*quarterly*)

☐ Individual \$60/year ☐ Institutional \$107/year ☐ In-training * \$45/year (Add \$15/year for subscriptions outside the U.S.; in Canada, also add 7% GST.)

☐ New Subscription ☐ Renewal

Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

PTT 55075

Payment Options:

☐ Check enclosed (payable to Williams & Wilkins)

☐ Bill me ☐ American Express

☐ MasterCard ☐ VISA Card # _____

Exp. date _____ Signature or P.O. # _____

Name _____

Address _____

City/State/Zip _____

* Please indicate institution/status _____

MD and PA subscribers must add state sales tax. Subscriptions outside the U.S. must be prepaid in U.S. dollars. In Japan, contact Igaku-Shoin, MYW, Ltd. (03) 5689-5400. Rates valid through October 31, 1994.

Return coupon to:

Williams & Wilkins

A WAVERLY COMPANY

P.O. Box 23291, Baltimore, MD 21203-9990

For credit card orders, call TOLL FREE:
1-800-638-6423 in the U.S. or Canada.

J4075S ZPTT

An important resource for everyone
involved in research on the
metabolism of drugs and chemicals

DRUG METABOLISM AND DISPOSITION

The Biological Fate of Chemicals


Editor: Vincent G. Zannoni, PhD, University of Michigan,
Ann Arbor, Michigan

DRUG METABOLISM AND DISPOSITION publishes *in vitro* and *in vivo* experimental results that bring readers significant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants, and preservatives. All papers are refereed to ensure a high standard of publication. The areas covered are:

- pharmacokinetics
- pharmacodynamics
- genetic, nutritional, and hormonal factors affecting the biological fate of chemicals
- toxicological consequences of xenobiotic metabolism

This journal should be a standard reference in all pharmacology and toxicology departments. It is also a valuable resource for all medicinal chemists involved in designing drugs and all biochemists involved with drug metabolism.

Bimonthly



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service — enter your multiyear subscription today!

Drug Metabolism and Disposition (bimonthly)

☐ Individual: \$85/yr ☐ Institutions: \$140/yr

(Please add \$20.00 outside the U.S.; in Canada, also add 7% GST.)

☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

name

address

city/state/zip

Williams & Wilkins
A WAVERLY COMPANY

DMD 55020

P.O. Box 23291
Baltimore, Maryland 21203-9990

Printed in USA

Broadway House
2-6 Fulham Broadway
London SW6 1AA England

J4020S ZDMD

Payment options:

☐ Check enclosed
☐ VISA

☐ Bill me

☐ MasterCard

☐ American Express

card *

signature/P.O. *

MD and PA subscribers must add state sales tax. Subscriptions from outside the US and Canada must be prepaid, in US dollars only. In Japan, contact Igaku-Shoin MYW, Ltd. (03) 5689-5400. Rates valid for orders received before October 31, 1994.

Please allow 8 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request.

Discounts available to members on all ASPET publications. SAVE 10% when ordering two. SAVE 15% when ordering three. SAVE 20% when ordering all four.



Previous Editors

- 1965** Avram Goldstein, *Editor*. Stanford University.
1968 Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.
1971 Steven E. Mayer, *Editor*, Palmer W. Taylor, *Associate Editor*. University of California at San Diego.
1975 George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.
1978 Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.
1983 Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.
1986 William A. Catterall, *Editor*; Joseph A. Beavo, Mont R. Juchau, Neil M. Nathanson, Daniel R. Storm, Frank F. Vincenzi, *Associate Editors*. University of Washington, Seattle.



Williams & Wilkins Quick Copies. Tell us today. Read it tomorrow.

You can get copies of any article published in all Williams & Wilkins journals. It's fast – because we're the primary source, we can fax it to you within **24 hours** of when we receive it. It costs less – there are **no copyright fees** and the **cost of faxing is included in the price**. It's affordable – look at the table to the right.

RATES, PER ARTICLE

1–5	pages	\$10
6–10	pages	\$12
11–15	pages	\$15
16–20	pages	\$18
21–25	pages	\$20
26+	pages	\$25

(\$20, Federal Express)

Fax, phone, or mail your citation to:

Williams & Wilkins Quick Copies

428 East Preston Street
Baltimore, MD 21202-3993
Call 1-800-354-9685 (toll free)
Fax 1-410-528-4312



Williams & Wilkins
A WAVERLY COMPANY

DDSD 54525

Newsworthy and timely
articles in your field


MOLECULAR PHARMACOLOGY

Editor: **T. Kendall Harden, PhD**, University of North Carolina
School of Medicine, Chapel Hill, North Carolina

Is your special interest receptors and neurotransmitters... drug metabolism... antibiotic and anticancer drug actions... or other areas related to the molecular basis of drug action? If so, you should be subscribing to **MOLECULAR PHARMACOLOGY**.

The editor's and editorial board's high standards ensure that the papers you read in **MOLECULAR PHARMACOLOGY** are on the cutting edge of research on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology are juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including such areas as molecular mechanisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anticancer drug action. Start your subscription today to ensure access to the most newsworthy papers in your field. **Monthly**

Call toll-free to start your subscription immediately, **1-800-638-6423**
from anywhere in the U.S. or Canada.



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscription today!

Molecular Pharmacology (monthly)

- ☐ Individual: \$105/yr ☐ Institutions: \$230/yr
(Please add \$30.00 outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

name _____

address _____

city state zip _____

Williams & Wilkins
A WAVERLY COMPANY

MOL 55049

P.O. Box 23291
Baltimore, Maryland 21203-9990

Printed in USA

Payment options:

- ☐ Check enclosed ☐ Bill me
☐ VISA ☐ MasterCard ☐ American Express

card # _____

signature / P.O. # _____

MD and PA subscribers must add state sales tax. Subscriptions from outside the US and Canada must be prepaid, in US dollars only. In Japan, contact Igaku-Shoin MYW, Ltd. (03) 5689-5400. Rates valid for orders received through October 31, 1994.

Please allow 8 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request.

Discounts available to members on all ASPET publications. SAVE 10% when ordering two. SAVE 15% when ordering three. SAVE 20% when ordering all four.

Broadway House
2-6 Fulham Broadway
London SW6 1AA England

J4049S ZMOL

